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Hormone replacement therapy (HRT) is used by post-menopausal women to alleviate 
symptoms associated with decreased endogenous estrogen levels, such as hot flashes and 
vaginal dryness. Although HRT is considered an effective treatment method, results from 
clinical trials such as those conducted by the Women’s Health Initiative (WHI) and Million 
Women Study (MWS) revealed that HRT usage is associated with increased risk of invasive 
breast cancer. The mechanism whereby the hormones used in HRT contribute to breast cancer 
risk is not fully understood. These hormones elicit their biological effects by binding to 
intracellular steroid receptors such as the estrogen (ER) and progesterone receptor (PR). For 
many years it was thought that the ER is the main steroid receptor implicated in breast cancer 
biology, however, data in the literature suggests that crosstalk between steroid receptors play 
an important role in the development and progression of this disease. Recent evidence suggests 
that the androgen receptor (AR) can function as a tumour suppressor and thus has the potential 
of being a prognostic marker and therapeutic target in breast cancer. Given that the AR has 
been shown to inhibit the transactivation function of ERα, this raised the question of whether 
the AR would also inhibit the transactivation function of the ERβ subtype. Moreover, 
considering that ERs have both transactivation and transrepression functions, studies 
investigating the influence of the AR on the transrepression function of both ERα and ERβ are 
lacking. This study therefore investigated whether the AR, in the absence or presence of known 
AR agonists (the natural AR ligand 5α-dihydrotestosterone (DHT)), the androgenic progestins, 
medroxyprogesterone acetate (MPA) and norethisterone-acetate (NET-A)), could modulate the 
transcriptional activity of the ERβ. The ER- and AR-negative MDA-MB-231 breast cancer cell 
line, transiently transfected with expression vectors for either ERα or ERβ and the appropriate 
promoter-reporter construct, was used as model system. The results showed that the unliganded 
or liganded AR has no effect on the transactivation function of ERβ on a synthetic estrogen 
response element (ERE)-containing promoter but downregulates the ERβ-driven mRNA 
expression of the endogenous PR gene. This study also shows estradiol (E2)-induced 
transactivation on a synthetic ARE- and an endogenous androgen response element (ARE)-
containing promoter via ERα. For transactivation via ERβ, similar results were only seen on 
the endogenous ARE-containing promoter. Moreover, we show for the first time that both the 
unliganded- and ligand-bound AR inhibits the transrepression function of ERα, while 
interestingly only the ligand-bound AR was able to inhibit the transrepression function of ERβ. 
No E2-induced cell proliferation was observed in the MDA-MB-231 cell line overexpressing 
either ERα or ERβ under the experimental conditions used. In conclusion, the results of this 
study are in agreement with previous evidence suggesting that the AR inhibits the activity of 
ERα. The precise physiological implications of these results remain to be determined. Finally, 
although the results from this study are preliminary and have certain limitations, it nonetheless 
highlights the fact that the role of the AR in breast cancer is a complex one. Thus, our findings 
may aid our understanding of crosstalk between the ER and AR signalling pathways, and how 
it contributes to the growth and survival of breast cancer cells.  




   _____________________________________________________ 
Hormoon vervangingsterapie (HVT) word deur na-menopousale vrouens gebruik om 
simptome geassosieerd met verlaagde endogeen estrogeenvlakke, soos warmgloede en 
vaginale droogheid, te verlig. Alhoewel HVT beskou word as ‘n effektiewe 
behandelingsmetode, toon resultate van kliniese toetse soos byvoorbeel die Vroulike 
Gesondheids Inisiatief (VGI) en Miljoen Vroue Studie (MVS) dat die gebruik van HVT ‘n 
toename in die risiko van indrigende borskanker veroorsaak. Die meganisme waardeur hierdie 
hormone, wat gebruik word in HVT, bydra tot die risiko van borskanker word nog nie ten volle 
verstaan nie. Hierdie hormone voer hul biologiese effekte uit deur te bind aan intrasellulêre 
steroïd reseptore soos die estrogeen (ER) en progesteroon (PR) reseptore. Vir baie jare was dit 
geglo dat die ER die hoof steroïd reseptor betrokke is in borskanker, maar data in die literatuur 
stel egter voor dat ‘n wisselwerking tussen steroïd reseptore ‘n belangrike rol in die 
ontwikkeling en bevordering van hierdie siekte speel. Onlangse bewyse dui daarop dat die 
androgeen reseptor (AR) as ‘n onderdrukker van gewasse kan funksioneer, en dus die 
potensiaal het om as ‘n prognostiese merker en terapeutiese teiken in borskanker te dien. Die 
feit dat die AR al getoon het om die transaktiverings funksie van die ERα te onderdruk, het 
gelei tot die opwekking van die vraag of die AR ook die transaktiverings funksie van die ERβ 
subtipe kan onderdruk. Verder, siende dat die ER’s beide transaktiverings en 
transonderdrukkings funksies het, is dit belangrik om in ag te neem dat daar ‘n te kort is aan 
navorsing wat die invloed van die AR op die transonderdrukkings funksie van beide ERα en 
ERβ ondersoek. Die huidige studie het dus ‘n ondersoek ingestel om te bepaal of die AR, in 
die afwesigheid of teenwoordigheid van bekende AR agoniste (die natuurlike AR ligand 5α-
dihidrotestosteroon (DHT), die androgeniese progestiene medroksieprogesteroon asetaat 
(MPA) en noretisteroon asetaat (NET-A)), die transkripsionele aktiwiteit van die ERβ kan 
verander. Die ER- en AR-negatiewe MDA-MB-231 borskankersellyn, tydelik getransfekteer 
met die uitdrukkingsvektore vir óf die ERα óf die ERβ en die toepaslike promotor-
rapporteerder konstruk, was gebruik as die model sisteem. Die resultate het getoon dat die AR 
geen effek op die transaktiverings funksie van die ERβ op ‘n sintetiese estrogeen respons 
element (ERE)-bevattende promotor het nie, maar dat dit wel die ERβ-gedrewe mRNS 
uitdrukking van die endogene PR geen onderdruk. Estradiool (E2)-geïnduseerde 
transaktivering op ‘n sintetiese androgeen response element (ARE) en ‘n endogene ARE-
bevattende promotor deur ERα word ook in hierdie studie aangedui. Soortgelyke resultate is 
ook waargeneem vir die transaktivering deur ERβ op ‘n endogene ARE-bevattende promotor. 
Verder, wys ons vir die eerste keer dat beide die ligandlose en ligand-gebonde AR die 
transonderdrukkings funksie van ERα inhibeer, terwyl interessant genoeg slegs die ligand-
gebonde AR die vermoë het om die transonderdrukkings funksie van ERβ te inhibeer. Onder 
hierdie gebruikte eksperimentele kondisies, was geen E2-geïnduseerde selproliferasie in die 
MDA-MB-231 sellyn, wat óf ERα óf ERβ ooruitdruk, waargeneem nie. In samevatting, die 
resultate van hierdie studie stem ooreen met vorige bewyse wat voorstel dat die AR die 
aktiwiteit van ERα onderdruk. Die presiese fisiologiese implikasies van hierdie resultate moet 
nog bepaal word. Ten slotte, alhoewel die resultate van hierdie studie slegs voorlopig is en 
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sekere beperkinge toon, beklemtoon dit nietemin die feit dat die rol van die AR in borskanker 
kompleks is. Dus, ons bevindings mag bydra tot die huigelike begrip van die wisselwerking 
wat tussen die ER en die AR seintransduksiepaaie voorkom, en mag ook help om te verstaan 
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Breast cancer accounts for about one fourth of all female cancers, and is the second leading 
cause of cancer-related death worldwide in women (Sommer and Fuqua 2001, Wang et al. 
2006, Yu et al. 2011, Seok-Jun et al. 2012, Chottanapund et al. 2013). Several factors have 
been identified, which increases the risk of developing breast cancer, and include genetics, 
epigenetics, lifestyle and endocrine therapy such as hormone replacement therapy (HRT) 
(Bergkvist et al. 1989, Black 1994, Colditz et al. 1995, McPherson et al. 2000, Rossouw et al. 
2002, Beral 2003). HRT is used by post-menopausal women to alleviate the symptoms 
associated with menopause, due to decreased estrogen levels. The symptoms of menopause 
include hot flashes, vaginal dryness, dysfunctional uterine bleeding, urogenital atrophy and 
psychological symptoms such as irritability, depression and insomnia (McKinlay et al. 1992, 
Ravn et al. 1994, Farquhar et al. 2009). HRT is given as estrogen alone to women who have 
undergone a hysterectomy, while women with an intact uterus are administered a combination 
of estrogen and a progestin, such as medroxyprogesterone acetate (MPA) or norethisterone 
acetate (NET-A) (Pike et al. 1997, Marsden 2003, Verkooijena et al. 2009, Mia et al. 2013). 
Progestins are added to reduce the risk of estrogen-induced endometrial hyperplasia (Gelfand 
and Ferenczy 1989, Pinto et al. 2003, Furness et al. 2009). Although HRT is considered an 
effective treatment for relieving menopausal symptoms, results from the Women’s Health 
Initiative (WHI) trial and the ‘Million Women Study’ (MWS) raised much alarm by showing 
that the use of HRT (estrogen alone and estrogen plus progestin) leads to increased risk of breast 
cancer in women (Rossouw et al. 2002, Beral 2003). Interestingly, recent studies have shown 
that there has been a decrease in breast cancer incidence, which has been suggested to be linked 
to a decline in HRT usage (Katalinic and Rawal 2008, Silvermana et al. 2011, Antoine et al. 
2014). It is thought that the primary cause of the reduction in the use of HRT over the last few 
years is due to the results of the WHI study (Chlebowski et al. 2003, Chlebowski et al. 2010, 
Holm et al. 2014). Understanding the mechanisms whereby hormones used in HRT increase 
Stellenbosch University  https://scholar.sun.ac.za
3 
 
women’s risk of developing breast cancer is essential for finding improved therapies for the 
treatment of breast cancer. It is known that the hormones used in HRT elicit their biological 
effects primarily via binding to the estrogen receptor (ER) or the progesterone receptor (PR), 
which are both members of the steroid receptor family (Osborne et al. 2001, Zilli et al. 2009, 
Kittler et al. 2013, Knutson and Lange 2014). The ER exists as two subtypes namely ERα and 
ERβ (Brandenberger et al. 1997, Enmark et al. 1997, Nilsson et al. 2001), while the PR is 
expressed as two isoforms called PR-A and PR-B, respectively (Kastner et al. 1990).  
Estrogen acting via ERα is considered to be the major etiological factor in breast cancer and 
stimulates breast cancer cell proliferation in ER-positive breast cancer cells (Jordan and Ford 
2011, Wu et al. 2012), while ERβ inhibits ERα-mediated cell proliferation (Gougelet et al. 
2005, Paris et al. 2012, Saxena et al. 2013). Studies have reported that the PR is also involved 
in breast cancer cell proliferation (Kalkhoven et al. 1994, Saitoh et al. 2005, Chen et al. 2012), 
with differential contributions of the PR isoforms being reported (Graham et al. 1996, Hopp et 
al. 2004, Stendahl et al. 2006, Giulianelli et al. 2013). For example, PR-B has been shown to 
have proliferative effects on breast cancer cell proliferation in the presence of its natural ligand 
progesterone (Conneely et al. 2003, Mulac-Jericevic et al. 2003, Boonyaratanakornkit et al. 
2008, Lanari et al. 2012), while PR-A has anti-proliferative properties (Saitoh et al. 2005, 
Boonyaratanakornkit et al. 2008, Khan et al. 2012). Although the ER and the PR are the best-
known prognostic markers of breast cancer (Silvermana et al. 2011), other steroid receptors 
such as the androgen receptor (AR) as well as the glucocorticoid receptor (GR), have been 
implicated in the etiology and pathogenesis of hormone-dependent breast cancer (Teulings et 
al. 1980, Conzen 2008). In fact, current evidence in the literature suggests that both the AR and 
GR display anti-proliferative effects and may thus have protective roles in breast cancer (Isola 
1993, Kuenen-Boumeester et al. 1996, Moinfar et al. 2003, Katalinic and Rawal 2008, Peters 
et al. 2009, Robinson et al. 2011). 
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It is noteworthy that some steroid receptors have been reported to be co-expressed in breast 
cancer tumours (Teulings et al. 1980, Ciocca et al. 2006, Gago et al. 2006, McNamara et al. 
2013). For example, it is known that the AR can be co-expressed with the ER in breast cancer 
tumours (Kuenen-Boumeester et al. 1996, Moinfar et al. 2003, Castellano et al. 2010). 
Interestingly, the expression of the AR in ER-positive breast cancer tumours is associated with 
a more favourable prognosis (Moinfar et al. 2003, Alshenawy 2012, Qu et al. 2013). Since the 
AR is expressed in most tumours, and as current therapies targetting estrogen signalling 
pathways have been shown to be ineffective in some patients due to the development of drug 
resistance (Martin et al. 2005, Ciruelos et al. 2014), a drug targetting the AR signalling 
pathway, could potentially be beneficial. It is important to understand the AR signalling 
pathways so that they can be targetted for the development of improved breast cancer therapies 
(Brentani et al. 1986, Birrell et al. 1998, McNamara et al. 2013). Therefore the objective of this 
literature review is to highlight the respective roles of the ER subtypes and the AR in breast 
cancer biology, by focusing on the mechanism of action of these steroid receptors when bound 
to either cognate or synthetic ligands. The implications of crosstalk between these receptors for 
breast cancer biology will also be discussed. 
 
1.2. Molecular mechanism of action of steroid receptors 
The intracellular effects of steroid hormones are mediated via binding to members of the steroid 
receptor family, a subfamily of the nuclear receptor family, and includes the ER, PR, AR, GR 
and mineralocorticoid receptor (MR) (Gasc and Baulieu 1987, Couse and Korach 1999, Lu et 
al. 2006, Helsen and Frank 2014). These receptors are ligand-activated transcription factors 
with similarities in their structure and function. 
1.2.1. General structure of steroid receptors 
As shown in figure 1.1, steroid receptors consist of five distinct functional domains, designated 
A-E, with ERα having an additional, carboxy-terminal F domain (Sommer and Fuqua 2001, 
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Balfe et al. 2004, Yang et al. 2008, Charitidi et al. 2009, Jin and Li 2010). The amino-terminal 
A/B domain contains the variable ligand-independent activation function (AF)-1 domain, which 
is important for protein-protein interaction with transcription factors and cofactors. This is 
followed by a highly conserved and centrally located DNA binding domain (DBD) (C-domain), 
a hinge region (D-domain) and a moderately conserved ligand binding domain (LBD) (E-
domain) situated at the carboxy-terminal (figure 1.1) (Jin and Li 2010, Forrest and Swaroop 
2012); reviewed in (Bain et al. 2007); reviewed in (Africander et al. 2011)).  
The DBD is highly homologous between the steroid receptors and comprises two zinc-finger 
motifs. The α-helix in the first zinc finger plays an important role in enabling the DBD to 
recognize specific palindromic DNA sequences known as steroid response elements (SREs) 
(Saji et al. 2005, Wu and Safe 2007, Charitidi et al. 2009, Helsen et al. 2012, McEwan 2012), 
while the second zinc finger is important for receptor homo- or heterodimerization (Shaffer and 
Gewirth 2002, Helsen and Frank 2014). The DBD is linked to the LBD via a short highly 
variable hinge region (D domain) (Wu and Safe 2007, Helsen et al. 2012, Hudson et al. 2014), 
which contains sites for post-translational modifications such as phosphorylation, methylation 
and sumoylation (Anbalagan et al. 2012, Helsen and Frank 2014). A second activation function 
domain (AF-2), is located in the LBD, and is necessary for recruiting various cofactors and for 
the induction of the transcriptional activity of the receptor (Kumar and Chambon 1988, Xu and 
Li 2003, Bain et al. 2007). It should be noted that the AF-2 transcriptional activity is ligand-
dependent, while that of AF-1 is ligand-independent. Ligand-dependent recruitment of 
coregulators to the AF-2 domain occurs via a hydrophobic cleft in this domain, which is 
shielded by an amphipatic α-helix in the absence of ligand (Griekspoor et al. 2007). The 
presence of ligand repositions this helix, thereby allowing coregulator binding via conserved 
LXXLL motifs found in the AF-2 domain (Weatherman et al. 1999). The sequence homology 
among the LBDs of steroid receptors is moderately conserved, with about a 50-70% sequence 
homology between the AR, GR, MR and PR, while the LBDs of the ER and PR share only 
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about 28% sequence homology, and that of the GR and ER only about 30% (Fuller 1991, Moras 
and Gronemeyer 1998, Maeda 2001). Lastly, the F domain, unique to ERα, contains functional 
elements which are responsible for functions such as controlling the interaction of ERα with 
steroid receptor coactivator-1 (SRC-1), and plays an important role in the receptor’s ability to 




Figure 1.1. A schematic illustration of the general structure of steroid receptors. The A/B region 
denotes the variable N-terminal domain containing the activation function-1 (AF-1) transactivation 
domain, C is the conserved DNA binding domain (DBD), D denotes the hinge region, and E is the 
carboxy-terminal moderately conserved ligand binding domain (LBD) containing the AF-2 
transactivation region. ERα, contains an additional F domain. The numbers represent the amino acid 
length of the steroid receptors. Figure taken from (Africander et al. 2011). 
Most unliganded steroid receptors are found in the cytoplasm, however, the ER and PR are 
found mainly in the nucleus (Brosens et al. 2004). These unliganded steroid receptors are 
sequestered in an inactive form in a large molecular complex organised around the molecular 
chaperone heat shock proteins, Hsp90 and Hsp70 (Pratt and Toft 2003, Gougelet et al. 2007). 
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When activated by ligand, steroid receptors modulate gene expression via two mechanisms, 
namely transactivation and transrepression. 
 
1.2.2. Transactivation 
Ligand-dependent transcriptional activation of genes occurs when small lipophilic hormones 
diffuse across the plasma membrane and bind to the LBD of the steroid receptor, leading to a 
conformational change in the steroid receptor and translocation to the nucleus of those steroid 
receptors found predominantly in the cytoplasm (figure 1.2) (Zhao et al. 2010, Murphy 2011). 
Once in the nucleus, the hormone-bound steroid receptor binds as a dimer to specific SREs 
found in the promoters of steroid responsive target genes (Beato and Klug 2000, Kumar and 
Litwack 2009). For example, the ER binds to SREs called estrogen response elements (EREs), 
while the PR binds to progesterone response elements (PREs). The SREs for PR, AR, MR and 
GR are highly homologous and consist of the palindromic sequence 5'-GGTACAnnnTGTTCT-
3’ (Beato et al. 1989), while the ER recognizes the alternative 5'-GGTCAnnnTGACC-3’ 
palindromic sequence (Klock et al. 1987, Klein-Hitpass et al. 1988, Brosens et al. 2004). The 
binding of a steroid receptor to the SRE, is followed by recruitment of coregulators, chromatin 
remodelling, leading to the recruitment of the basal transcriptional machinery (Beato and Klug 
2000, Perissi and Rosenfeld 2005, Lu et al. 2006). This leads to the activation of gene 
transcription in a process known as transactivation (figure 1.2). 
 
1.2.3. Transrepression 
Steroid receptors can also negatively regulate transcription of genes by binding to DNA-bound 
transcription factors such as nuclear factor kappa-B (NFκB), activator protein-1 (AP-1) and 
CCAAT enhancer binding protein (C/EBP) (Ueda et al. 1994, Harrington et al. 2003, Pascual 
and Glass 2006, Frasor et al. 2009) in a process called transrepression (Harrington et al. 2003, 
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Lu et al. 2006, Carter and Stephen 2014). Although the ER, AR, PR and MR have all been 
shown to interact with NFκB to repress the expression of target genes (Kalkhoven et al. 1996, 
Palvimo et al. 1996, Ray et al. 1997, Aarnisalo et al. 1998, McKay and Cidlowski 1999, 
Kalaitzidis and Gilmore 2005, Sønder et al. 2006, Matter and Handschin 2007, Bergmann et 
al. 2010, Chantong et al. 2012, Drummond and Fuller 2012, Africander et al. 2014), the 
mechanism of transrepression is best studied for the GR through its interaction with NFkB and 
AP-1 (McKay and Cidlowski. 2000, Pascual and Glass 2006, Newton and Holden 2007, De 
Bosscher et al. 2008, Beck et al. 2009). NFκB is a transcription factor that is activated by many 
stimuli such as the tumor promoter, phorbol 12-myristate 13-acetate (PMA) (Lee et al. 2002, 
Chang et al. 2005) and proinflammatory cytokines such as tumour necrosis factor-alpha TNF-
α (Scarpati and Sadler 1989, Ravi and Bedi 2004, Lee et al. 2007, Beck et al. 2009). Upon 
ligand binding to the GR, the liganded GR translocates to the nucleus where it tethers to DNA-
bound NFκB, thereby inhibiting NFκB-driven gene expression (figure 1.2) (Ghosh et al. 1998, 
De Bosscher et al. 2008). Similar to the mechanism of transactivation, but less understood, 
transrepression also involves the binding of multiprotein complexes on DNA and the 
modulation of chromatin structure (Kassel and Herrlich 2007, Africander et al. 2011). 
Considering that all steroid receptors have essentially identical mechanisms of action for 
transactivation, it is probable that they repress genes by a similar mechanism to that of the GR. 
As this study focuses on the transcriptional activity of the ER and AR, a more detailed 










Figure 1.2. An illustration of the classical (general) mechanism of action of steroid receptors. SR: 
steroid receptor, SRE: steroid response element, Hsp90: heat shock protein 90, NFκB: nuclear factor 
kappa B, AP-1: activator protein. Co-regulators (represented by cofactors in the diagram), result in the 
opening of the chromatin structure and recruitment of basal transcription machinery. Redrawn from 
(Africander et al. 2011). 
 
1.3. Molecular mechanisms of estrogen action 
1.3.1. Production of estrogens and their physiological actions  
Estrogens are female sex steroid hormones that play an important role in various tissues of the 
human body (Gougelet et al. 2005, Thomas and Potter 2013). Figure 1.3 shows the many 
examples of these roles, which include maintenance of bone density as well as the growth and 
proliferation of breast tissue (Gruber et al. 2002). 




Figure 1.3. Estrogens act on multiple organ systems. The figure illustrates the diverse actions of 
estrogens on different organs in the human body. Figure taken from (Gruber et al. 2002). 
 
Three types of estrogens are produced within the female body namely, estrone (E1), 17β-
estradiol (E2), and estriol (E3) (Thomas and Potter 2013, Samavat and Kurzer 2015). E2 is 
mainly produced in the ovaries (Simpson 2002, Tsuchiya et al. 2005), while E1 and E3 are 
primarily produced in the liver from E2 (Gruber et al. 2002, Tsuchiya et al. 2005). As shown in 
figure 1.4, E2 is formed from testosterone either
 directly by the action of the aromatase (CYP19) 
enzyme, or indirectly through the reduction of E1 by 17β-hydroxysteroid dehydrogenase (17β-
HSD) isozymes. The 17β-HSD2 enzyme oxidises testosterone to androstenedione, which is 
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aromatized to E1 (Tsuchiya et al. 2005, Knower et al. 2013, Thomas and Potter 2013, Samavat 
and Kurzer 2015). E3 is synthesized via the action of the enzyme 17β-HSD1 on the intermediate 
16α-hydroxyestrone, which is produced from E1 via cytochrome P450 3A4/5 (CYP3A4 or  
CYP3A5) (Huang et al. 1998). E1 is the inactive form of E2 (Andersson and Moghrabi 1997, 
Abplanalp et al. 1999) and has been shown to inhibit cell division of the MCF-7 breast cancer 
cell line (Jozan et al. 1979). Although previous studies have suggested that high levels of E3 
protect women against breast cancer (Lemon 1975, Wotiz et al. 1978, Lemon et al. 1989), some 
studies have shown that E3 can increase the growth of breast cancer cells and activate expression 
of ERE-containing genes to the same extent as E2 (Katzenellenbogen 1984, Pang and Faber 
2001, Diller et al. 2014). As E2 is the most biologically active estrogen, with circulating levels 
in the high picomolar to nanomolar range in the reproductive phase of women (Chatterton et 
al. 2003, Watson et al. 2008, Thomas and Potter 2013, Samavat and Kurzer 2015), we will only 











Figure 1.4 legend on next page. 
  
(CYP3A4/5) 
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Figure 1.4. An illustration of the estrogen metabolism pathway. Testosterone is the main precursor 
for estrogen production, which involves different cytochrome P450 enzymes. Aromatase is the major 
enzyme involved in the production of E2 and E1 from the androgen precursors (testosterone and 
androstenedione), 17β-HSD plays a role in the production of E1 and E3, while CYP3A4/5 is involved in 
the production of E3 from E1. Adapted from (Thomas and Potter 2013). 
 
E2 is released into the bloodstream after production and ~37% binds to sex hormone binding 
globulin (SHBG) and ~60% binds to albumin for transport to target tissues (Dunn et al. 1981), 
while only ~3% is left free or unbound (Siiteri 1987, Pardridge 1988, Petra 1991, Gruber et al. 
2002). Free E2 diffuses into target tissues where its biological actions are primarily mediated 
by binding to estrogen receptors (Matthews and Gustafsson 2003, Balfe et al. 2004, Faulds et 
al. 2012), and these actions include the normal female reproductive processes as well as playing 
a role in the regulation of a number of diseases. Examples of the latter include osteoporosis, 
coronary heart disease (CHD), Alzheimer’s disease and hormone-dependent cancers, which 
include endometrial, ovarian, prostate and breast cancer (Ingemar 2000, Paranjape et al. 2005, 
Li-Min et al. 2012, Wen-Yang et al. 2012, Brown and Hankinson 2014, Li et al. 2014, Hamed 
and Mindy 2015). It is important to note that the role of E2 in the above-mentioned processes 
can be either positive or negative. Examples of positive effects include reports that high levels 
of E2 prevents the development of Alzheimer’s disease (Giacobini 1998, Xing et al. 2013, Li et 
al. 2014), while the use of E2 plus progestin in HRT has been associated with a decreased risk 
of osteoporosis (Lee et al. 2013, Nelson et al. 2013) and coronary heart disease (CHD) 
(Grodstein et al. 1996, Paranjape et al. 2005, Hodis and Mack 2014). In contrast to these 
positive effects, E2 has been shown to increase the risk of endometrial and ovarian cancer via 
several mechanisms such as cell proliferation, decreased apoptosis and increased DNA damage 
(Henderson and Feigelson 2000, Cunat et al. 2004, Liang et al. 2009, Zhang et al. 2012, Brown 
and Hankinson 2014, Ribeiro and Freiman 2014). Similarly, long-term exposure to E2 has been 
shown to be linked to an increased risk of breast cancer and may lead to tumor growth via 
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mechanisms such as increased DNA damage and cell proliferation (Fox et al. 2008, Santen et 
al. 2009, Yue et al. 2013). 
 
1.3.2. Diverse molecular pathways are involved in ER-mediated estrogen 
actions 
1.3.2.1. ER subtypes 
The main actions of estrogen are genomic and are mediated by the ER subtypes. The two main 
functional ER subtypes, ERα and ERβ, are transcribed from different genes (Menasce et al. 
1993, Matthews and Gustafsson 2003). ERα is a 66 kDa protein, which was discovered in the 
late 1960s (Toft et al. 1967) and was isolated and purified from the human MCF-7 breast cancer 
cell line in the late 1980s (Walter et al. 1985, Green et al. 1986). It is expressed in the female 
reproductive system (breast, ovary, uterus), male reproductive system (testis, epididymis, 
prostate gland) and various other tissues such as the pituitary gland, kidney, bladder, liver, heart, 
thymus and adrenal gland (Ogawa et al. 1998, Pearce and Jordan 2004). ERβ is a 56 kDa 
protein, which was only identified in 1996 (Kuiper et al. 1996, Mosselman et al. 1996, 
Katzenellenbogen and Korach 1997, Enmark and Gustafsson 1999), and like ERα, ERβ is 
expressed in the female and male reproductive systems as well as various other tissues such as 
the bladder, lung, adrenal and heart (Iwao et al. 2000, Roger et al. 2001, Farquhar et al. 2009).  
Human ERα and ERβ have similar structural domains (figure 1.5) and differ mainly in their 
amino acid length (Nilsson et al. 2001, Pearce and Jordan 2004, Ascenzi et al. 2006). The N-
terminal domain of the ERs has only about 30% identity, with ERβ being reported to lack AF-
1 activity (Pearce and Jordan 2004). The DBD of the two ERs has 96% identity, suggesting that 
both receptors would bind to similar sites in target genes. The hinge region, like the N-terminal 
domain, is not highly conserved between the ERs (30% homology). The LBD’s of the two 
subtypes have a 53% homology, and show slight differences in ligand binding specificity 
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(Mosselman et al. 1996, Pearce and Jordan 2004). For example, E2 has been shown to have a 
slightly higher binding affinity for ERα as compared to ERβ, while phytoestrogens such as 




Figure 1.5. Structural homology between human ERα and ERβ. The various domains are 
represented by the letters A-F, with the amino acid sequence homology between the individual domains 
shown as a percentage. The A/B region denotes the variable N-terminal domain containing the AF-1 
domain, C is the DBD, D denotes the hinge region which connects the DBD to the LBD, E is the LBD, 
which contains the AF-2 domain. ERα, contains an additional F domain. The numbers represent the 
amino acid length of the steroid receptors. Figure redrawn from (Pearce and Jordan 2004, Africander et 
al. 2011). 
 
1.3.2.2. Molecular pathways 
ERs can regulate biological processes through several distinct signaling pathways, which 
include both ligand-dependent and ligand-independent mechanisms (figure 1.6). The classical 
genomic mechanism of steroid receptor action is ligand-dependent (illustrated in figure 1.2), 
and for the ER, involves E2 binding to the ER, and the subsequent direct binding of the E2-
bound ER to an ERE (figure 1.6A) or tethering to another transcription factor (figure 1.6B) 
(Gruber et al. 2002, Simoncini et al. 2004, Yager and Davidson 2006, Heldring et al. 2007). 
These nuclear actions lead to increased gene expression of target genes via the ERE, and 
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decreased transcription of target genes via tethering to DNA-bound transcription factors such 
as NFκB and AP-1 (Stein and Yang 1995, Galien and Garcia 1997, Yamei et al. 2007, 
Robertson et al. 2010). Interestingly, the ER has been shown to repress NFκB signalling at 
various levels of transcriptional regulation (Kalaitzidis and Gilmore 2005, Drummond and 
Fuller 2012). For example, the ER can repress NFκB signaling by (i) suppressing inhibitor of 
kappa B (IκB) kinase (IKK) activity, (ii) preventing the degradation of IκB proteins, (iii) 
blocking NFκB from binding to DNA and (iv) competing with NFκB for coactivators 
(Kalaitzidis and Gilmore 2005, Drummond and Fuller 2012). However, there is limited 
information in the literature regarding ER subtype-specific-mediated mechanisms of 
transrepression. At least one study has shown that E2 acting via both ER subtypes, can repress 
the  expression of an NFκB containing promoter-reporter construct (Visser et al. 2013), while 
one other study showed that E2 acting via ERα was able to cause repression of three TNF-α-
induced proinflammatory genes (Cvoro et al. 2011).  
Although the classical mechanism of action can take hours to achieve maximal E2-induced gene 
responses (Gruber et al. 2002, Simoncini et al. 2004, Heldring et al. 2007), some of the ligand-
activated ER responses are more rapid (Watsona et al. 1999, Gruber et al. 2002, Wong et al. 
2002, Simoncini et al. 2004, Song et al. 2005, Song and Santen 2006). An example of the latter 
is the non-genomic mechanism involving membrane-bound ER (figure 1.6C) and most likely 
involves other membrane bound receptors such as G-protein-coupled receptors (GPRCs). In 
this mechanism the ligand activates the membrane-associated ER, leading to the initiation of 
signaling cascades via second messengers (SM). These SM affect ion channels or increase nitric 
oxide (NO) levels in the cytoplasm, thereby causing rapid physiological responses without 
involving gene regulation (Hall et al. 2001, Stefan et al. 2001, Björnström and Sjöberg 2005, 
Heldring et al. 2007, Silva et al. 2010, Ozgyin et al. 2015). Lastly, growth factor (GF) signalling 
(figure 1.6D) can lead to the activation of protein kinase cascades, which result in the 
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phosphorylation of ERs and the subsequent binding to EREs, thus modulating gene regulation 




Figure 1.6. Molecular pathways used in the regulatory actions of ERs. The classical (direct) pathway 
(A) involves ligand-bound ER binding directly to EREs leading to increased transcription of target 
genes. Alternatively, the tethered pathway (B) involves indirect binding to DNA via protein-protein 
interactions with other transcription factors resulting in decreased transcription of target genes. The non-
genomic pathway (C) involves ligand activation of membrane receptors, which leads to the initiation of 
signaling cascades via second messengers (SM), increasing nitric oxide (NO) levels and ultimately 
leading to altered physiological responses. Lastly the ligand-independent mechanism (D) involves 
activation via growth factor (GF) signalling leading to the activation of kinases that phosphorylate the 
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1.4. The role of E2 and ER subtypes in breast cancer biology 
1.4.1. E2 and ERα 
Numerous clinical and epidemiological studies have indicated that exposure to E2 is associated 
with increased risk of developing breast cancer (Clemons and Goss 2001, Yager and Davidson 
2006). The cellular mechanisms by which E2 increases breast cancer risk is an area of ongoing 
study but at least two possibilities have been suggested (figure 1.7) (Miller 2004). Firstly, E2 
binds to the ER causing altered gene expression, which results in uncontrolled or excessive cell 
proliferation (figure 1.7A). Interestingly, the E2-induced proliferative effects on breast cancer 
cells in humans can be either direct or indirect (Clemons and Goss 2001). The direct E2-induced 
mechanism of cell proliferation is initiated by the induction of enzymes and proteins involved 
in nucleic acid synthesis and activation of specific oncogenes (Clemons and Goss 2001), while 
the secretion of hormones such as prolactin and the production of GFs such as transforming 
growth factor alpha (TGFα) initiates the indirect mechanism of cell proliferation (Clemons and 
Goss 2001). The second mechanism whereby it has been suggested that E2 causes increased 
risk of breast cancer comes from evidence suggesting that the metabolism of E2 to genotoxic 
agents causes direct DNA mutations (figure 1.7B) (Yager and Leihr 1996, Miller 2004, Yager 
and Davidson 2006). E2 is metabolized via catechols (organic compounds), particularly 2- or 
4- hydroxyestradiol or hydroxyestrone, to produce quinones. The latter interacts with and 
mutates DNA, initiating carcinogenesis (figure 1.7B) (Miller 2004, Yager and Davidson 2006). 
Considering that this thesis focusses on some parts of the pathway shown in figure 1.7A, and 
that the ERα subtype has predominantly been implicated in the development and progression 
of breast cancer, only the role of E2 via the ERα will be further discussed.  
 
 






Figure 1.7. Two pathways indicating the mechanisms of E2 carcinogenesis. The diagram illustrates 
two mechanisms that contribute to the initiation of breast cancer. (A) ER-mediated increase in cell 
proliferation and (B) metabolism of E2 to genotoxic agents such as quinones, causing DNA mutation. 
Redrawn from (Miller 2004). 
 
ERα is expressed in almost 70% of breast cancers (Jensen and Jordan 2003, Pearce and Jordan 
2004, Conzen 2008). Both in vivo and in vitro studies have reported that ERα is crucial for the 
promotion of breast cancer cell growth and survival by E2 (Cunha et al. 1997, Couse and Korach 
1999, Frasor et al. 2003, Hartman et al. 2009, Brisken and O’Malley 2010, Powell et al. 2012, 
Huang et al. 2014b). For example, despite the presence of high levels of E2, no breast cancer 
tumours were detected in ERα knock-out mice (Couse and Korach 1999). Current therapies for 
E2-dependent breast cancer are thus directed towards either (i) preventing the interaction of E2 
with the ERα using selective ER modulators (SERMs) or selective estrogen receptor 
downregulators (SERDs) (Jordan 2007, Patani and Martin 2014) or (ii) by inhibiting the 
synthesis of E2 using aromatase inhibitors (AI’s) (Mirzaie et al. 2013, Nantasenamat et al. 2013, 
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Akçay and Bayrak 2014). The latter includes compounds such as letrozole and anastrozole, 
which bind reversibly to the aromatase enzyme, thereby decreasing the levels of E2 available to 
promote tumour formation or progression (Kijima et al. 2005, Gil et al. 2013). Studies have 
shown that anastrozole decreases cell proliferation in breast cancer cell lines (Miller and 
Jackson 2003, Kijima et al. 2005, Gil et al. 2013) and reduces tumour size when administered 
to breast cancer patients (Miller and Jackson 2003, Kijima et al. 2005, Gil et al. 2013). SERMs 
on the other hand are ligands that bind the ERα and act as either agonists or antagonists 
depending on the type of tissue (Howell et al. 2004, Renoir 2012). In the breast however, 
SERMs act as ERα antagonists (Macgregor and Jordan 1998, O'Regan and Jordan 2002) and 
include tamoxifen, the most frequently used drug in first-line clinical therapy for the treatment 
and prevention of hormone-sensitive breast cancer (Ogawa et al. 1998, Girault et al. 2006, 
Zervoudis et al. 2014, Lim et al. 2015), as well as raloxifene (Kijima et al. 2005, Zhang et al. 
2013). Both these ligands have been shown to inhibit breast cancer cell growth (Speirs et al. 
1999, Fowler et al. 2004, Howell et al. 2004, Speirs et al. 2004, Kijima et al. 2005, Lange 2008) 
by antagonizing E2-induced gene expression and proliferation. SERDs are pure antagonists that 
do not have any agonist activity via the ERα in any tissue (Macgregor and Jordan 1998, O'Regan 
and Jordan 2002, Howell et al. 2004, Renoir 2012), and ICI 182,780, also known as fulvestrant 
or faslodex, and RU58668 (Pearce and Jordan 2004, Renoir 2012, Ciruelos et al. 2014). 
Clinically, faslodex is used as second-line treatment when patients fail to respond to tamoxifen 
(Lynn 2004, Martin et al. 2005, Howell 2006, Ciruelos et al. 2014). SERDs inhibit ERα-
mediated transcriptional activity by down-regulating ERα levels, as these ligands target the ERα 
for proteasome-dependent degradation (Alarid et al. 1999, Lonard et al. 2000, Meiyun et al. 
2003, Howell 2006, Renoir 2012, Ciruelos et al. 2014). 
Several studies have shown that E2-bound ERα promotes the development and progression of 
breast cancer by upregulating the expression of genes, such as c-myc, c-fos and cyclin D1, that 
play a role in the cell cycle and induce breast cancer cell (Helguero et al. 2005, Hartman et al. 
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2009, Brisken and O’Malley 2010), and/or by eliciting anti-apoptotic effects through the 
upregulation of the anti-apoptotic protein Bcl-x and downregulation of the pro-apoptotic protein 
Bax (Helguero et al. 2005). Not only does E2 stimulate breast cell proliferation and inhibit 
apoptosis via ERα, but it also plays a role in cell invasion and metastasis (Clarke et al. 2003, 
Jiang et al. 2007). For example, E2 stimulates the invasive and metastatic potential of the ERα-
positive MCF-7 breast cancer cell line (Shafie and Liotta 1980, Osborne et al. 1985, Cos et al. 
1998).  
 
1.4.2. ERβ and its interplay with ERα 
Immunohistochemical analysis has shown that both ERα and ERβ are expressed in the normal 
breast, and that ERβ expression is more abundant than ERα (Clarke et al. 1997, Russo et al. 
1999, Speirs et al. 2004). However, more ERα than ERβ is expressed during the development 
of breast cancer (Leygue et al. 1998, Roger et al. 2001, Murphy et al. 2003, Shaaban et al. 
2003). Interestingly, a small number of breast cancers express only ERα (~14%) or only ERβ 
(~18%) (Murphy et al. 2003, Skliris et al. 2008, Leung et al. 2012). It is important to note that 
the current evidence in the literature suggests that co-expression of ERα and ERβ in breast 
cancer patients is linked to a better prognosis than when ERα or ERβ alone is expressed (Omoto 
et al. 2001, Roger et al. 2001, Paruthiyil et al. 2004, Lin et al. 2007). This is due to the ability 
of ERβ to inhibit ERα-mediated cell proliferation as well as its ability to induce apoptosis 
(Leygue et al. 1998, Dotzlaw et al. 1999, Speirs et al. 1999, Zhao et al. 2008). For example, 
evidence from in vitro studies indicate that co-expression of ERβ in ERα-positive breast cancer 
cells inhibits the proliferative effects of E2 via ERα (Williams et al. 2007, Hartman et al. 2009). 
In fact, even in the absence of E2, co-expression of ERβ with ERα in the same cell line, promotes 
anti-proliferative and anti-tumour effects (Paruthiyil et al. 2004, Lin et al. 2007). It has been 
proposed that ERβ exhibits these effects by decreasing the expression of the E2-responsive pro-
proliferative (c-myc, cyclin A and cyclin D1) (Paruthiyil et al. 2004) and anti-apoptotic (Bcl-2 
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and Bcl-x) (Nilsen et al. 2000, Song and Santen 2003) genes, and/or increasing expression of 
anti-proliferative genes such as p21Cip1 and p27Kip1 (Paruthiyil et al. 2004, Lin et al. 2007). In 
contrast to ERα, the role of ERβ in breast cancer cell invasion is not well-studied, but the 
evidence from at least two studies suggest that ERβ inhibits breast cancer cell invasion, both in 
vivo and in vitro (Lazennec et al. 2001, Thomas et al. 2012). Furthermore, studies have shown 
that ERβ can antagonise ERα-mediated effects by either interfering with the recruitment of co-
activators required for ERα-mediated actions, or by forming a heterodimer with ERα and 
thereby affecting the recruitment of this receptor to the promoters of E2-responsive genes such 
as the PR (Fox et al. 2008).  
The presence of ERβ in ERα-negative breast cancers is, however, not considered favourable. 
Studies indicate that in the absence of ERα, ERβ promotes proliferation by increasing the 
expression levels of the proliferative markers Ki67 (O'Neill et al. 2004, Skliris et al. 2006) and 
cyclin A (Fox et al. 2008). Although the molecular mechanism underlying this phenomenon is 
unclear, at least one study in the literature suggest that the phosphorylation status of ERβ may 
play a role (Tremblay et al. 1999). These authors showed that the phosphorylation of residues 
within the AF-1 domain in ERβ, due to an increase in mitogen-activated protein kinases 
(MAPK) activity, enhances the recruitment of the co-activator SRC-1, and thereby leads to 
enhanced transcriptional activity of ERβ (Tremblay et al. 1999).  
 
1.5. Role of androgens and the AR in breast cancer biology 
1.5.1. Androgens 
For many decades, E2 and the ERs were thought to be the main etiological factors implicated 
in breast cancer pathogenesis. However, recent evidence suggests that androgens and the AR 
are not only role players in prostate cancer (Weller et al. 2014, Karantanos et al. 2015), but may 
also play a role in the development and progression of breast cancer (Nicolás et al. 2007, Hu et 
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al. 2011, Robinson et al. 2011, Kotsopoulos and Narod 2012, Li et al. 2013). The reported 
function of androgens in breast cancer is, however, contradictory, as at least one study shows 
stimulatory effects (Birrell et al. 1995), while a number of other studies indicate inhibitory 
effects on the growth of breast cancer cells (Hackenberg et al. 1991, Birrell et al. 1998, Greeve 
et al. 2004). Stimulatory effects are supported by studies showing that the most potent natural 
androgen, 5α-dihydrotestosterone (DHT), has pro-proliferative effects in MCF-7 and MDA-
MB-453 breast cancer cell lines (Birrell et al. 1995, Lin et al. 2009), suggesting an increased 
risk of breast cancer. In contrast, the apoptotic and anti-proliferative effects of the potent 
synthetic androgen, mibelorone (MIB) in T47-D and ZR-75-1 cells, may provide a mechanism 
to support its reported protective role in breast cancer pathogenesis (Nicolás Díaz-Chico et al. 
2007, Dimitrakakis 2011, Kotsopoulos and Narod 2012, Coss et al. 2014, Lakis et al. 2014). 
Whether androgens elicit anti-proliferative or proliferative effects in cell lines appear to be 
dependent  on various factors including, the specific cell line and androgen used, the 
concentration of the androgen used, as well as the absence or presence of E2 (Birrell et al. 1995, 
Birrell et al. 1998).  
In addition to the above-mentioned in vitro studies, both in vivo and clinical studies (Dauvois 
and Labrie 1989, Dauvois et al. 1989, Lin et al. 2009, Dimitrakakis 2011) have also shown that 
androgens can either inhibit or stimulate the growth of tumours in breast cancer patients (Sourla 
et al. 1998, Dimitrakakis et al. 2003). Clinical evidence suggests that the subcutaneous 
administration of testosterone in postmenopausal women may be beneficial as it reduces the 
incidence of breast cancer (Bitzer et al. 2008, Dimitrakakis and Bondy 2009, Glaser and 
Dimitrakakis 2013). The clinical use of testosterone, however, is also associated with negative 
effects. This is due to the aromatization of testosterone to E2, thereby possibly increasing the 
risk of breast cancer (Cauley et al. 1999, Somboonporn and Davis 2004). Studies have 
suggested that DHT, which unlike testosterone cannot be aromatized to E2, may reduce tumour 
growth. However, this effect depends on factors such as androgen concentration and cell line 
Stellenbosch University  https://scholar.sun.ac.za
23 
 
used. Although some studies suggest that DHT may provide a new treatment option for breast 
cancer patients as it cannot be aromatized to E2 (Ando et al. 2002, Chottanapund et al. 2013), 
DHT may have masculinizing side-effects and thus newly-developed selective androgen 
receptor modulators (SARMs) may be a better treatment option (Gao and Dalton 2007, Bhasin 
and Jasuja 2009). 
 
1.5.2. Androgen receptor (AR) 
At the molecular level, androgens mediate their effects via the AR (Birrell et al. 1998, Kandouz 
et al. 1999, Birrell et al. 2007). This intracellular steroid receptor is predominantly cytoplasmic 
in its ligand-free state and upon androgen binding, the AR translocates to the nucleus where, 
like the ER, it either positively or negatively regulates target gene expression (Gobinet et al. 
2002, Lee and Chang 2003). Some AR regulated genes such as the prostate homeobox (NKX3) 
and kallikreins (KLK5 and KLK3, also known as prostate-specific antigen (PSA)), are 
associated with breast cancer pathogenesis. For example in vivo studies have shown that NKX3 
inhibits ER signalling and therefore can be a potential regulator of hormone response in breast 
cancer (Corthals et al. 2000, Xu et al. 2001, Nelson et al. 2002, Holmes et al. 2008, Wang et 
al. 2009, Asch-Kendrick et al. 2014). Although PSA is generally regarded as a prostate cancer-
specific gene, heightened PSA levels have also been observed in malignant breast cancers. The 
physiological relevance of the latter is not yet clear, although it has been suggested that PSA 
promotes breast cancer tumour progression and metastasis (Yu et al. 1998, Black et al. 2000). 
As mentioned earlier, a number of studies have suggested that the AR, which is expressed in 
approximately 70-90% of primary breast tumours (Søreide et al. 1992, Garay and Park 2012) 
and in 25% of advanced breast tumours (Søreide et al. 1992, Birrell et al. 1998, Garay and Park 
2012, Chottanapund et al. 2013), may play a critical role in breast cancer biology (Hu et al. 
2011, Robinson et al. 2011, Li et al. 2013). It is proposed that the expression of the AR in breast 
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tumours inhibits tumour growth and metastasis of cancer, and as a result reduces the number of 
breast cancer deaths (Søreide et al. 1992, Birrell et al. 1995, Kulshreshtha et al. 2010, 
Chanplakorn et al. 2011, Loibl et al. 2011, Yu et al. 2011, McNamara et al. 2014b). Considering 
that the majority of breast cancers express the AR, and taking into account that the above-
mentioned studies suggest that the AR inhibits breast cancer progression, it has been proposed 
that the current clinical classification of breast cancers, which focusses only on ERα, PR and 
human epidermal growth factor receptor 2 (HER2) status, should be altered to include the AR 
(Farmer et al. 2005, McNamara et al. 2014b). For example, basal (ERα-negative, AR-negative); 
luminal (ERα-positive, AR-positive); molecular apocrine (ERα-negative, AR-positive) (Farmer 
et al. 2005). The latter subtype is often referred to as triple negative breast cancer (TNBC) due 
to the lack of ERα, PR and HER2 expression (Nicholas et al. 2003, Anestis et al. 2015). 
Luminal cancer is subdivided into luminal A (low Ki67 index, slow tumour growth) and B (high 
Ki67 index, high tumour growth) (Yanagawa et al. 2012), with the AR more abundantly 
expressed in luminal A tumours (Park et al. 2010, Loibl et al. 2011, Tsang et al. 2014). The co-
expression of AR with ER is associated with smaller tumour size and no signs of relapse during 
endocrine treatment and chemotherapy (Castellano et al. 2010, Hu et al. 2011, Park et al. 2011, 
Tsang et al. 2014). The protective effect of the AR is attributed to its ability to inhibit the 
activity of ERα in patients with luminal breast tumours (Peters et al. 2009, Castellano et al. 
2010). The role of the AR in TNBC is controversial. A study has shown that the expression of 
the AR in TNBC is associated with an increase in lymph node metastases and number of breast 
cancer deaths (Hu et al. 2011). This is thought to be due to the AR acting as a surrogate ERα 
and activating transcription of ERα-regulated genes thereby promoting tumour progression in 
patients (Robinson et al. 2011). However, other studies indicate that the presence of the AR in 
TNBC results in a reduced proportion of lymph node metastases and a better prognosis (Sutton 
et al. 2012, Tang et al. 2012). Furthermore, at least one study has shown that AR expression 
has no influence on TNBC (Mrklić et al. 2013).  
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In conclusion, although studies in the literature on the effects of androgens and the AR on breast 
cancer are contradictory, the AR is currently being considered as a therapeutic target for the 
treatment of breast cancer (Chottanapund et al. 2013). In ERα-positive (luminal) breast cancers, 
targetting AR activation may be ideal as the unliganded- or ligand-bound AR inhibits the 
transcriptional activity of ERα (Peters et al. 2009, Fioretti et al. 2014). However, in ERα-
negative (molecular apocrine/TNBC) breast cancers, it may be beneficial to inhibit the actions 
of the AR as it may function as a surrogate ERα in the absence of the latter (Fioretti et al. 2014). 
From the above, it is clear that the function of the AR in breast cancer is determined by whether 
or not the ER is present. In the next section, we will thus discuss the current knowledge in the 
literature on the association between the ER subtypes and the AR in breast cancer. 
 
1.5.3. Crosstalk between the ER subtypes and the AR  
A number of clinical studies have showed that AR expression in ER-positive breast tumours is 
associated with lower grade disease, reduced invasiveness and longer disease-free survival 
(Castellano et al. 2010, Hu et al. 2011, Loibl et al. 2011, Park et al. 2011, Yu et al. 2011, Park 
et al. 2012, Qu et al. 2013, Vera-Badillo et al. 2013, Witzel et al. 2013, Tsang et al. 2014). 
However, these studies do not distinguish between the two ER subtypes expressed in these 
breast tumours. To the best of our knowledge, the few in vitro studies that have been conducted 
to gain insight into the interplay between the ER subtypes and AR in breast cancer mainly 
focused on the ERα subtype. 
Figure 1.8 shows the proposed mechanisms by which the AR can either promote or inhibit 
breast cancer pathogenesis. In ERα-positive breast cancer (figure 1.8A), the AR acts as a 
competitor of ERα and thus suppresses ERα-mediated tumour growth (Birrell et al. 1995, Szelei 
et al. 1997, Lanzino et al. 2005, Macedo et al. 2006, Peters et al. 2009, Hickey et al. 2012). 
The above-mentioned is supported by the results from an in vitro study by Peters et al. (2009) 
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showing that in ERα-positive breast cancer cells, the AR inhibits the transactivation function 
of ERα, as well as ERα-mediated cell proliferation (Peters et al. 2009). In ERα-negative breast 
cancer (figure 1.8B), it is proposed that the AR levels increase and that there are changes in 
cofactor interactions, resulting in the AR mimicking the function of ERα, thereby sustaining 
tumour growth (Robinson et al. 2011, Hickey et al. 2012).  
Several mechanisms have been identified whereby the AR inhibits the actions of ERα. For 
example, it has been shown that the AR can bind directly to EREs (Peters et al. 2009, Rizza et 
al. 2014), thereby preventing ERα from interacting with the ERE and as a result inhibiting the 
transactivation function of ERα (Peters et al. 2009, Hickey et al. 2012, Lamb et al. 2014). 
Considering that both transactivation and transrepression of ER target genes play a role in the 
regulation of breast cancer cell survival and proliferation, it would be interesting to know 
whether the transrepression function of ERα would also be inhibited by the AR. Furthermore, 
ERα and the AR have been shown to interact with similar co-regulatory molecules (Lanzino et 
al. 2005, Fioretti et al. 2014), therefore it is possible that when co-expressed these receptors 
may compete for these molecules. One such example is the AR associated (ARA70) protein, a 
known AR co-activator that also acts as an ERα co-activator (Lanzino et al. 2005). Lastly, ERα 
and the AR have similar non-genomic activities. This means that the AR as well as ERα interact 
with similar accessory proteins such as modulator of non-genomic activity of estrogen receptor 
(MNAR), which is important for cell membrane actions of these receptors. The ability of the 
AR to interact with these proteins prevents ERα from associating with these proteins thus 
leading to ERα being unable to regulate signalling pathways at the cell membrane (Fioretti et 
al. 2014). Unlike, the numerous studies examining the interaction between the AR and ERα in 
breast cancer, not much is known about the interplay between ERβ and the AR. 
 
 






Figure 1.8 Proposed mechanism of the tumour suppressor vs. oncogenic roles of the AR in breast 
cancer. (A) The AR can act as a tumour suppressor by competing with ERα for binding to EREs, leading 
to the suppression of ERα-mediated growth. (B) In the absence of ERα, the AR mimics the actions of 
ERα thereby becoming an oncogene. The red arrow indicates an increase in AR levels. Adapted from 




ERα-positive breast cancer 
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For over a century it has been appreciated that E2 and the ER play critical roles in breast cancer 
biology and their role in breast cancer has been extensively studied. ERα has been reported to 
promote cell growth and survival, while ERβ inhibits ERα-mediated cell proliferation. 
However, emerging evidence suggests that other steroid receptors, like the AR, are also 
involved in the regulation of breast cancer growth (Birrell et al. 1998, Brys 2000, Hartman et 
al. 2012, Shah et al. 2013, Lakis et al. 2014). Interestingly, the evidence in the literature 
suggests that the precise function of the AR in breast cancer is dependent on whether or not 
ERα is present, with little known about the link between the AR and ERβ. Figure 1.9 
summarises the current knowledge on the interplay between the ER subtypes and the AR in 
breast cancer. The illustration shows that both the AR and ERβ can inhibit cell survival and 
proliferation, directly and indirectly, by suppressing the activity of ERα (Peters et al. 2009, 
Need et al. 2012). Also shown is the fact that not much is known about whether the AR can 
have an effect on the activity of ERβ. Given that both the AR and ERβ elicits growth-inhibitory 
effects in the presence of ERα, and that the role of the AR and ERβ changes to promote breast 
cancer development in the absence of ERα, it is important to elucidate the influence of the AR 
on the function of ERβ. Furthermore, although it is known that the AR modulates the 
transactivation function of ERα, one cannot exclude the fact that ERs elicit their biological 
activity via both transactivation and transrepression mechanisms. Thus, it is important to also 
study the effects of the AR on the transrepression function of the ER subtypes. This is 
particularly important in the light of the fact that inflammation is known to promote the 
development and progression of breast cancer (Niu et al. 2012, Bhatelia et al. 2014, Suman et 
al. 2015), and repression of NFκB-regulated genes via the ER subtypes potentially reduces the 
risk of inflammation-induced breast cancer (Visser et al. 2013). 
 
 





Figure 1.9. Interplay between the ER subtypes and the AR in breast cancer. ERα promotes cell 
survival and proliferation, while ERβ antagonizes ERα-mediated cell proliferation. The AR has been 
shown to have the ability to inhibit cell proliferation both directly and indirectly by suppressing the 
activity of ERα. – and Τ denote inhibition of activity, + shows activation of activity, the blue arrows 
demonstrate that the effect is towards ERα while the purple arrow demonstrates that the effect is towards 
ERβ. 
 
1.7. Aims of the study 
The evidence in literature suggests that the AR decreases the transactivation function of ERα 
and that the decrease is more pronounced in the presence of AR ligand (Peters et al. 2009). 
Furthermore, it has been reported that the AR mimics the function of ERα as it can bind to 
EREs, but that ERα cannot bind to an ARE. Whether the AR has the same effect on the 
transactivation function of ERβ and whether the latter can transactivate via an ARE, is not well 
studied. Moreover, considering that ERs have both transactivation and transrepression 
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functions, studies investigating the influence of the AR on the transrepression function of both 
ERα and ERβ are lacking.  
Thus, the main aim of the current study was to investigate the influence of the AR on both the 
transactivation and transrepression functions of the ER subtypes, with the main focus being on 
ERβ. The ER- and AR-deficient MDA-MB-231 human breast cancer cell line was used as an 
in vitro model system for breast cancer to investigate the following: 
1. The validation of the experimental system used by Peters et al. (2009).  
 
2. The effect of increasing concentrations of human AR, in the absence and presence of AR 
ligands, on the transactivation function of human ERβ via a synthetic ERE-containing promoter 
reporter construct. 
 
3. The effect of increasing concentrations of the AR on the transactivation function of both ER 
subtypes on an endogenous ER-regulated gene. 
 
4. The ability of both ER subtypes to transactivate via a synthetic and an endogenous ARE-
containing promoter. 
 
5. The effect of the AR on the transrepression function of both ER subtypes via a synthetic 
NFκB-containing promoter. 
 
6. The ability of the AR to modulate ERα- or ERβ-mediated cell proliferation. 
 























The plasmids expressing the human ERα (pSG5-ERα) and ERβ (pSG5-ERβ) were received 
from Prof. Frank Gannon (European Molecular Biology Laboratory, Heidelberg, Germany) 
(Gilles et al. 2000). A plasmid expressing the human AR, pSVARo, (Kastner et al. 1990) was 
obtained from Prof Frank Claessens (University of Leuven, Belgium) (Brinkmann et al. 1989). 
The promoter-reporter construct vit-ERE-TATA-luciferase containing two copies of the 
estrogen response element (ERE) previously described by (Hall et al. 2002) was obtained from 
Prof Ken Korach (National Institute of Environmental Health Sciences, North Carolina, USA), 
while the p(IL6ĸB)350hu.IL6Pluc
+ promoter reporter construct was obtained from Prof. Guy 
Haegeman (University of Gent, Belgium) (Plaisance et al. 1997). The pGL2 basic vector, 
purchased from Promega (Madison, USA), was used as a filler plasmid and the pTAT-GRE-
E1b-luc, driven by the E1b promoter containing two copies of the rat TAT-GRE, was obtained 
from Dr. G. Jenster (Erasmus University of Rotterdam, Netherlands) (Sui et al. 1999). The latter 
promoter-reporter construct will be referred to as an ARE-luc. 
 
2.1.1. Plasmid DNA preparation 
Escherichia coli DH5α cells were made competent using the calcium chloride method and 
transformed using the heat shock method (Sambrook et al. 1989). A starter culture was prepared 
by growing a single colony of the transformed bacteria in 5 ml Luria-Bertani (LB) medium in 
the presence of 50 µg/ml ampicillin (all plasmid vectors used in this study (mentioned in 2.1) 
contain an ampicillin-resistant gene) for 6 hours while shaking at 37°C. Thereafter 5 ml of the 
starter cultures were transferred into 250 ml fresh LB and 50 µg/ml ampicillin. The latter was 
incubated for 16 hours at 37°C to allow cells to reach exponential growth. Plasmid DNA was 
purified using the PureYieldTM Plasmid Maxiprep System (Promega, Madison, USA) according 
to the manufacturer’s instructions. Briefly, the cultures were centrifuged for 10 minutes at 5000 
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x g and the supernatants discarded. Each pellet was resuspended in 12 ml Cell Resuspension 
Solution, before lysis in 12 ml Cell Lysis Solution. Lysis was stopped by adding 12 ml 
Neutralization Solution, followed by centrifugation of the lysate at 14 000 x g for 30 minutes. 
Two columns were used to purify the plasmid DNA using a vacuum manifold. The PureYieldTM 
clearing column was set on top of the PureYieldTM maxi binding column. The lysate was 
decanted into the PureYieldTM clearing column and maximum vacuum was applied. The 
PureYieldTM clearing column was removed after the lysate had passed through to the 
PureYieldTM maxi binding column. The latter was then washed with 5 ml Endotoxin Removing 
Buffer, followed by 20 ml Column wash while applying maximum vacuum. The column was 
subsequently dried for 5 minutes under vacuum, and then inserted into a 50 ml tube. Nuclease-
free water was added to the column prior to centrifugation in a swing bucket rotor at 2000 x g 
for 5 minutes. The eluate containing the plasmid DNA was collected and the DNA 
concentration determined using a Nanodrop 1000 (Thermo Fisher Scientific, South Africa). 
Restriction enzyme digests and agarose gel electrophoresis were used to determine the size and 
integrity (quality) of the plasmid DNA. 
 
2.2. Test compounds 
The test compounds used in this study included 17β-estra-1,3,5(10)-etriene-3,17 diol [17-β-
estradiol; (E2)], 5α-androstan-17β-ol-3-one [5α–dihydrotestosterone; (DHT)], 6α-methyl-17α-
hydroxyprogesterone acetate [medroxyprogesterone acetate; (MPA)] and 17α-ethynyl-19-
nortesterone 17β-acetate [norethisterone acetate; (NET-A)]. All the test compounds and 
phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma-Aldrich, South Africa. Test 
compounds were prepared in absolute ethanol (EtOH) and stored in glass vials at -20oC. 
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2.3. Cell culture 
The human breast cancer cell line, MDA-MB-231 (a kind gift from Prof. Guy Haegemann, 
University of Gent, Belgium), was maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Sigma-Aldrich, South Africa) containing 4.5 g/ml glucose, phenol-red and 
supplemented with 10% (v/v) fetal calf serum (FCS) (Separations, South Africa), 100 IU/ml 
penicillin (Sigma-Aldrich, South Africa) and 100 µg/ml streptomycin (Sigma-Aldrich, South 
Africa). COS-1 cells (African monkey kidney fibroblast cells), obtained from the American 
Type Culture Collection (ATCC, Virginia, USA), were maintained in DMEM containing 
phenol red supplemented with 10% (v/v) FCS, penicillin (100 IU/ ml) and streptomycin (100 
µl/ml). All the cell lines were maintained in 75 cm2 flasks (Greiner Bio-One International, 
Austria) at 37oC with a relative humidity of 90% and 5% CO2. The cell lines were regularly 
tested for mycoplasma infection using Hoechst staining (Freshney 1987), and only mycoplasma 
negative cells were used in experiments. 
 
2.4. Promoter reporter assays 
2.4.1. Transactivation 
MDA-MB-231 cells were seeded into 96-well plates (Porvair Science, United Kingdom) at a 
density of 1.75 x 104 cells per well in DMEM containing phenol red, 10% (v/v) FCS, 100 IU/ml 
penicillin and 100 µg/ml streptomycin. The cells were then incubated for 24 hours to allow 
complete adherence to the surface of the plates. The following day, the cells were rinsed once 
with sterile 1x PBS and the medium was replaced with phenol red-free DMEM supplemented 
with 5% (v/v) charcoal treated FCS, 100 IU/ml penicillin and 100 µg/ml streptomycin. Phenol-
red free DMEM was used because it is well-known that phenol-red has estrogenic activity 
(Welshons et al. 1988). The cells were subsequently transiently transfected with either 100 ng 
of the vit-ERE-TATA-luciferase construct and 2.5 ng of the expression vector for human ERα 
(pSG5-hERα) or 50 ng vit-ERE-TATA-luciferase construct and 2.5 ng of the expression vector 
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for human ERβ (pSG5-hERβ), in the absence or presence of 2.5, 5 or 10 ng of the expression 
vector for human AR (pSVARo), using X-tremeGENE HP DNA transfection reagent (Roche 
Molecular Biochemicals, South Africa) according to the manufacturer’s instructions. The filler 
plasmid pGL2 basic was used to ensure a constant total DNA concentration of 112.5 ng. 
Transfection and subsequent treatment conditions were similar to that described in Peters et al. 
(2009). Briefly, 3 hours after transfection, the cells were incubated with 0.1% (v/v) EtOH 
(control) or 1 nM E2, DHT, MPA or NET-A (agonist mode), or 1 nM E2 in the absence or 
presence of 1 nM DHT, MPA or NET-A (antagonist mode) for 36 hours. The cells were 
subsequently washed with sterile 1x PBS and lysed by adding 25 µl passive lysis buffer (0.2% 
(v/v) Triton-X 100, 10% (v/v) glycerol, 2.8% (v/v) Tris-phosphate-ethylenediaminetetra-acetic 
acid (EDTA) and 1.44 mM EDTA) per well. The plates were then placed on a shaker for 15 
minutes at room temperature, before being frozen at -20oC, as the freeze-thawing facilitates 
effective lysis. On thawing of samples, 10 µl of the lysates were assayed for luciferase activity 
using the Luciferase Assay system (Promega luciferase assay reagent, Madison, USA) and a 
Veritas microplate luminometer (Turner biosystems, USA). In addition, 5 µl of the cell lysate 
was used to determine the protein concentration by the Bradford protein determination 
(Bradford 1976). The luciferase values obtained for all experiments (expressed as relative light 
units (RLUs)) were normalised relative to the protein concentration for each sample. Some 
results are expressed as fold induction with the EtOH value set as one, while other results are 
expressed as the fold induction value in the presence of 1 nM E2 set as 100% with all other 
values calculated relative to that. The reported values are averages of at least 3 independent 
experiments, with each condition performed in triplicate. 
 




The MDA-MB-231 cell line was seeded into 96-well plates at a density of 1.75 x 104 cells per 
well in DMEM containing phenol-red. After 24 hours, the cells were transiently transfected 
with 2.5 ng of either pSG5-hERα or pSG5-hERβ and 100 ng p(IL6ĸB)350hu.IL6Pluc
+, in the 
absence or presence of 2.5, 5 or 10 ng pSVARo, using the X-tremeGENE HP DNA transfection 
reagent (Roche Molecular Biochemicals, South Africa) according to the manufacturer’s 
instructions. The filler plasmid, pGL2 basic, was used to ensure a constant total DNA 
concentration of 112.5 ng. After 3 hours the cells were incubated with 0.1 % (v/v) EtOH in the 
absence or presence of 10 ng/ml PMA. For agonist mode, cells were treated with 10 ng/ml PMA 
in the absence (0.1% (v/v) EtOH) or presence of 1 nM E2, DHT, MPA or NET-A for 36 hours. 
For antagonist mode, cells were treated with 1 nM E2 in the absence and presence of 1 nM 
DHT, MPA or NET-A for 36 hours. Cells were lysed and analysed as in 2.4.1. The luciferase 
values obtained for all experiments were normalized relative to the protein concentration for 
each sample. Results are expressed as either the fold induction with the EtOH value set as one 
in order to quantify the extent of PMA induction, or as normalised percentage response with 
the value for EtOH + PMA set as 100% in order to determine the extent of repression obtained. 
 
2.5. Western blot analysis 
To determine the steroid receptor content in the MDA-MB-231 human breast cancer cell line, 
cells were plated into 6-well plates (Porvair Science, United Kingdom) at a density of 2.5 x 105 
cells per well. For positive controls, COS-1 cells were seeded into 12-well plates (Porvair 
Science, United Kingdom) at a density of 1 x 105 cells per well and transiently transfected with 
250 ng of the respective steroid receptor expression vector  for human ERα, ERβ or AR (pSG5-
ERα, pSG5-ERβ or pSVARo). Untransfected COS-1 cells were used as negative controls. After 
48 hours, the cells were washed with 1x PBS and placed on ice, before lysis with 80 µl (6 well 
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plate) or 100 µl (12 well plate) 2x sodium dodecyl sulphate (SDS) sample buffer (1 M Tris- 
hydrogen chloride (HCl) (pH 6.8), 10% (w/v) SDS, 0.1% (w/v) bromophenol blue, 2% (v/v) β-
mercaptoethanol and 20% (v/v) glycerol) (Sambrook et al. 1989). Cells were removed from the 
wells using a cell scraper and then transferred into a 1.5 ml Eppendorf tube (Eppendorf AG, 
Hamburg, Germany). All lysates were denatured by boiling for 10 minutes at 97oC. Protein 
samples were separated on a 10% SDS-polyacrylamide gel by performing SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) at 100 V for 15 minutes and 200 V for 45 minutes using 1x 
SDS running buffer (3.5 mM SDS, 25 mM Tris-HCl, 192 mM Glycine). After electrophoresis, 
the samples on the acrylamide gel were transferred onto a hybond Enhanced 
Chemiluminescence (ECL) nitrocellulose membrane (Amersham Biosciences, USA) at 180 
mA for 90 minutes using 1x transfer buffer (25 mM Tris-HCl (pH 7), 192 mM glycine and 10% 
methanol). The membranes were blocked for 2 hours in 10% (w/v) fat-free milk powder in 1x 
TBS (Tris Buffered Saline - 50 mM Tris-HCl and 150 mM NaCl) containing 0.1% (v/v) Tween-
20 (TBST). Thereafter, the membranes were rinsed with 1x TBST and incubated with specific 
primary antibodies directed against the steroid receptors of interest (Santa Cruz Biotechnology 
Inc, Europe), for 16 hours at 4oC. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as a loading control. The membranes were then washed with TBST (once for 15 minutes 
and three 5 minute washes), before incubating with horseradish peroxidase (HRP)-conjugated 
secondary antibodies (goat anti-rabbit or anti-mouse) (Santa Cruz Biotechnology Inc., Europe) 
at room temperature for 90 minutes. The dilutions for all antibodies used in this study are 
summarised in Table 2.1. The membranes were washed again as indicated above, and then 
visualized using ClarityTM ECL western blotting substrate (Biorad, South Africa) and medical 
X-ray film (Africa X-Ray Industrial and Medical (Pty) LTD., South Africa). 
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ERα (M-20) 1:500 goat anti-rabbit 1:1 000 
ERβ (H-150) 1:1 000 goat anti-rabbit 1:1 000 
AR (441) 1:2 000 goat anti-mouse 1:5 000 
GR (H-300) 1:4 000 goat anti-rabbit 1:5 000 
MR (H-300) 1:500 goat anti-rabbit 1:5 000 
PR-A/B (AB-52) 1:500 goat anti-rabbit 1:2 000 
GAPDH (0411) 1:4 000 goat anti-mouse 1:15 000 
 
2.6. Total RNA isolation and complementary DNA (cDNA) synthesis  
Human MDA-MB-231 cells were seeded into 12-well plates at a density of 1 x 105 cells per 
well. Cells were transfected with 33.3 ng of either pSG5-hERα or pSG5-hERβ expression 
vectors in the absence and presence of increasing concentrations of the pSVARo (0, 33.3, 66.6 
and 133.2 ng, respectively) and pGL2 basic expression vectors to ensure a constant total DNA 
concentration of 166.5 ng, using X-tremeGENE HP DNA transfection reagent (Roche 
Molecular Biochemicals, South Africa) according to the manufacturer’s instructions. Twenty 
four hours later the cells were treated for 12 hours with either 0.1% (v/v) EtOH, 1 nM E2 or 
DHT, or equimolar amounts of both E2 and DHT in phenol red-free DMEM supplemented with 
5% (v/v) charcoal treated FCS. Following a single PBS wash, the total RNA was isolated from 
the cells using Tri-reagent (Sigma-Aldrich, South Africa) according to the manufacturer’s 
instructions. Briefly, the cells were lysed by adding 400 µl Tri-reagent and stored overnight at 
-80oC, as the freeze-thawing facilitates lysing of the cells. On thawing, the lysates were 
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transferred to 1.5 ml microcentrifuge tubes and incubated for 5 minutes at room temperature. 
Thereafter 80 µl chloroform was added and the samples were vortexed for 1 minute. The 
samples were incubated for 3 minutes at room temperature before centrifugation at 20 800 x g 
for 15 minutes at 4oC. The aqueous phase was transferred to a clean microcentrifuge tube and 
an equal volume of ice-cold isopropanol was added. Samples were vortexed for 1 minute and 
incubated for 15 minutes at room temperature, followed by centrifugation at 20 800 x g for 15 
minutes at 4oC to pellet the RNA. The pellets were subsequently washed by adding 500 µl 75% 
(v/v) EtOH, vortexing for 1 minute, and centrifugation at 6800 x g for 5 minutes at 4oC. The 
supernatant was aspirated and the RNA pellets were air-dried for 10 minutes on ice before 
dissolving pellets in 15 µl diethyl pyrocarbonate (DEPC)-treated water. The RNA concentration 
was measured using a Nanodrop ND-100 Spectrophotometer (Inqaba Biotec, South Africa) and 
the A260/280 ratios were determined. All RNA samples were pure as indicated by A260/280 ratios 
between 1.9 and 2.1 in a 10 mM Tris buffer (Sambrook et al. 1989). The integrity of the RNA 
was confirmed on 1% (w/v) denaturing formaldehyde agarose gels by the presence of intact 
28S and 18S ribosomal bands. All RNA samples were stored at -80oC. The total RNA extracted 
from the transfected MDA-MB-231 cell line was reverse transcribed using the transcriptor first 
strand cDNA synthesis kit (Roche Applied Science, South Africa) according to the 
manufacturer’s instructions. Briefly, 0.5 µg total RNA was added to 2.5 µM anchored-
oligo(dT)18-primer and if needed, PCR-grade water was added to a final volume of 6.5 µl. The 
template-primer mixture was incubated at 65oC for 10 minutes to denature the RNA secondary 
structures and immediately placed on ice. Thereafter the following was added: 2 µl of 1x 
transcriptor reverse transcriptase reaction buffer (8 mM MgCl2), 0.25 µl of protector RNase 
inhibitor (20 U/µl), 1 µl of deoxynucleotide mix (1 mM per nucleotide) and 0.25 µl of 
transcriptor reverse transcriptase (10 U/µl) (Roche Applied Science, South Africa). The 
samples were then incubated at 50oC for an hour in order for reverse transcription to take place. 
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The reaction was stopped by incubating the samples at 85oC for 5 minutes in order to inactivate 
the transcriptor reverse transcriptase. The cDNA samples were stored at –20oC. 
 
2.7. Realtime quantitative polymerase chain reaction (qPCR) 
Realtime qPCR was performed using the StepOne Plus Real Time PCR system (Applied 
Biosystems, South Africa) according to the manufacturer’s instructions. The qPCR reaction 
mixture was prepared by adding a final concentration of 0.2 µM forward and reverse primers 
respectively (table 2.2), 5 µl 1x SYBR Green (Kapa biosystems, South Africa) and PCR-grade 
water to a final volume of 9 µl per sample. Thereafter, 1 µl cDNA template or PCR-grade water 
(negative control) was added. The samples were incubated for 3 minutes at 95oC to activate the 
Taq polymerase, followed by denaturation for 15 seconds at 95oC. The thermal cycling profiles 
for PR, PSA (prostate specific antigen) and GAPDH genes are summarized in table 2.3. 
Agarose gel electrophoresis and melting curve analysis were used to confirm the presence of a 
single amplicon. A cDNA dilution series was used to generate a standard curve to determine 
the amplification efficiency of each primer set (Addendum). The efficiencies were 1.96, 1.94 
and 2.12 for PR, PSA and GAPDH, respectively. The relative transcript levels of target genes 
were normalized to the relative transcript levels of GAPDH by using the mathematical model 
described by (Pfaffl 2001). 
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Table 2.2. Primer sequences for genes investigated in this study. 
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2.8. Methyl Thiazolyl Tetrazolium (MTT) cell proliferation assay 
The MDA-MB-231 cell line was seeded into 96-well plates at a density of 1 x 104 cells per 
well. The following day, cells were washed with 200 µl pre-warmed PBS (37oC) followed by 
the addition of 200 µl phenol-red free DMEM, supplemented with 10% (v/w) charcoal-stripped 
FCS. The cells were subsequently transfected with either 2.5 ng pSG5-hERα, or pSG5-hERβ 
or pGL2 basic using X-tremeGENE HP DNA transfection reagent according to the 
manufacturer’s instructions. After 24 hours, the medium was aspirated and the cells were 
treated for 48 hours with 0.1% (v/v) (EtOH) or 1 nM E2 in phenol-red free DMEM 
supplemented with 10% (v/w) charcoal-stripped FCS only. After 48 hours, 50 µl of the 
colorimetric MTT solution (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) 
(Sigma-Aldrich, South Africa) prepared by dissolving 5 mg/ml MTT in pre-warmed PBS and 
filter-sterilising the solution, was added to each well together with 150 µl phenol red free 
DMEM containing 10% (v/w) charcoal-stripped FCS. The yellow MTT tetrazolium salt is 
reduced by metabolically active cells to an insoluble purple formazan precipitate that can be 
solubilized with dimethyl sulfoxide (DMSO) and quantified spectrophotometrically. After a 4 
hour incubation with the MTT solution, the medium was aspirated and 200 µl DMSO was added 
to each well to solubilize the crystals. The plate was covered with foil and incubated at room 
temperature for 5 minutes, while shaking. The absorbance was then read at 540 nm in a Power 
wave 340 microtiter plate reader (Biotek, Winooski, USA). Results were expressed as fold 
induction with the value for EtOH set as one. 
 
2.9. Data manipulation and statistical analysis 
The GraphPad Prism® Software version 5.3 was used for data manipulation, graphical 
representations and statistical analysis. Two-way ANOVA analysis of variance and 
Bonferroni’s (compares all pairs of columns) post-tests was used for statistical analysis of 
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grouped data. Unpaired t-tests were used for column graphs with only two sets of data. One-
way ANOVA analysis of variance with Bonferroni’s (compare all pairs of columns) post-tests 
as well as Newman-Keuls (compare all pairs of columns) post-tests was used for all column 
graphs with more than two sets of data. Statistically significant differences are indicated by (*, 
**or ***) to indicate p<0.05, p<0.01 or p<0.001, respectively, whereas no statistical difference, 
(p>0.05) is indicated by ns. The letters a, b and c are used to indicate statistical significant 
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3.1. Validating the experimental system 
A study by Peters et al. (2009) showed that the unliganded AR decreases the transcriptional 
activation of ERα, and that in the presence of liganded AR, this decrease was in a concentration 
dependent manner. This raised the question of whether the AR could decrease the activity of 
ERβ in a similar manner. To address this question, the model system used by Peters and co-
workers was firstly validated, by following similar transfection and treatment conditions in the 
same cell line (see chapter 2, section 2.4.1). Briefly, the ER and AR negative human MDA-
MB-231 breast cancer cell line (absence confirmed by western blot in figure 3.1) was transiently 
transfected with an ERα expression vector and an estrogen response element (ERE)-driven 
reporter construct containing two copies of the ERE, in the absence or presence of increasing 
concentrations of an AR expression vector.  
 
Figure 3.1. The ER subtypes and the AR are not expressed in the MDA-MB-231 breast cancer cell 
line. Whole cell extracts were prepared from the human MDA-MB-231 (MDA) cell line. Untransfected 
COS-1 cells were used as the negative control (–ve ctrl), COS-1 cells transiently transfected with pSG5-
hERα, pSG5-hERβ or pSVARo expression vectors, respectively were used for the positive controls (+ve 
ctrl). Protein lysates were analysed by western blotting using antibodies specific to ERα, ERβ, AR or 
GAPDH, respectively.  GAPDH was used as the loading control.  
 
The cells were subsequently treated with 1 nM E2, the most biologically active estrogen 
(Samavat and Kurzer 2015). As expected and shown in figure 3.2A, 1 nM E2 caused significant 
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transactivation (p<0.001) of an ERE-containing promoter-reporter construct via ERα (3.8-fold). 
Consistent with the results shown by Peters and co-workers, the result in figure 3.2B shows that 
the AR inhibits E2-induced ERα transactivation. However, it should be noted that the current 
study shows a concentration-dependent decrease in the presence of the unliganded AR, and that 
the decrease is more pronounced than the decrease observed by Peters et al. (2009). 
Furthermore, to exclude a mechanism whereby the AR decreases ERα protein expression, we, 
like Peters and co-workers, used western blot analysis to show that increasing concentrations 
of the AR do not affect ERα protein levels (figure 3.3). 
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Figure 3.2 legend on next page. 
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Figure 3.2. The AR decreases E2-induced ERα transactivation function. .Human MDA-MB-231 
breast cancer cells were transiently transfected with pSG5-hERα and the vit-ERE-TATA-luciferase 
reporter construct, in the absence or presence of increasing concentrations of pSVARO (1x, 2x or 4x 
molar excess), and where needed pGL2basic, using X-tremeGENE HP DNA transfection reagent 
according to the manufacturer’s instructions. After 3 hours cells were treated with 0.1% (v/v) EtOH 
(control) or 1 nM E2 for 36 hours. The luciferase values were normalised to the protein concentrations, 
and expressed as luciferase/protein (luc/prot). The fold induction at 1 nM E2 via ERα is shown in (A), 
while in (B) the fold induction in (A) was set as 100%, with induction in the presence of various 
concentrations of AR calculated relative to that. The results indicate the average (± SEM) of at least 
three independent experiments, with each condition performed in triplicate. Statistical analysis was 
performed using the unpaired t-test (A) and one-way ANOVA analysis of variance with Bonferroni 
(compare all pairs of columns) (B) post-tests.  
   








































Figure 3.3 legend on next page. 
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Figure 3.3. The overexpressed AR does not affect the protein levels of overexpressed ERα in the 
MDA-MB-231 breast cancer cell line. (A) Human MDA-MB-231 breast cancer cells were transiently 
transfected as in figure 3.2. Protein lysates were analysed by western blotting with antibodies specific 
to ERα, AR or GAPDH (loading control). Protein lysates from COS-1 cells transfected with pSG5-hERα 
and pSVAR0 were used as positive controls (+ve), while lysates from untransfected COS-1 cells were 
used for the negative control (–ve ctrl). (B) Western blots were quantified using UN-SCAN-IT software. 
 
3.2. The AR does not affect the transcriptional activation of ERβ on a 
synthetic ERE-containing promoter 
As the experimental system had been validated, we next investigated the effect of increasing 
concentrations of the AR on ERβ protein levels as well as on ERβ transcriptional activation. 
The human MDA-MB-231 cell line was transiently transfected with 2.5 ng pSG5-ERβ and 50 
ng vit-ERE-TATA-luciferase in the absence or presence of increasing concentrations of 
pSVARo (2.5 ng, 5 ng or 10 ng) and where needed, pGL2basic, to ensure that the total amount 
of DNA transfected remained constant. The cells were subsequently treated with 1 nM E2 for 
36 hours. The western blot in figure 3.4 indicates that, similar to the observation for ERα (figure 
3.3), the AR does not affect ERβ protein levels. Having shown that the AR does not affect ERβ 
protein levels, the effects of increasing concentrations of the AR on the transcriptional 
activation of ERβ was next investigated. The result in figure 3.5A shows that 1 nM E2 caused 
significant transactivation (p<0.001) of an ERE-containing promoter-reporter construct via 
ERβ. However, in contrast to the results obtained for ERα (figure 3.2B), the AR does not affect 
E2-induced transcriptional activation via ERβ (figure 3.5B). 
 
 












































Figure 3.4. The overexpressed AR does not affect protein levels of overexpressed ERβ in the MDA-
MB-231 human breast cancer cell line. (A) Human MDA-MB-231 breast cancer cells were transiently 
transfected with pSG5-hERβ and the vit-ERE-TATA-luciferase reporter construct, in the absence or 
presence of increasing concentrations of pSVARO, (1x, 2x or 4x molar excess), and where needed 
pGL2basic, using X-tremeGENE HP DNA transfection reagent according to the manufacturer’s 
instructions. After 3 hours cells were treated with 0.1% (v/v) EtOH (control) or 1 nM E2 for 36 hours. 
Protein lysates were analysed by western blotting with antibodies specific to ERβ, AR or GAPDH 
(loading control). Protein lysates from COS-1 cells transfected with pSG5-hERβ and pSVAR0 were used 
as positive controls (+ve), while lysates from untransfected COS-1 cells were used for the negative 
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Figure 3.5. The AR does not decrease the transactivation function of E2-bound ERβ. Human MDA-
MB-231 breast cancer cells were transfected as in figure 3.4. The luciferase values were normalised to 
the protein concentrations, and expressed as luciferase/protein (luc/prot). The fold induction at 1 nM E2 
via ERβ is shown in (A), while in (B) the fold induction in (A) was set as 100%, with induction in the 
presence of various concentrations of AR calculated relative to that. The results indicate the average (± 
SEM) of at least three independent experiments, with each condition performed in triplicate. Statistical 
analysis was performed using the unpaired t-test (A) and one-way ANOVA analysis of variance with 
Bonferroni (compare all pairs of columns) (B) post-tests.  
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3.3. The AR ligands do not augment the effect of the unliganded AR  
Although we established that the unliganded AR does not affect E2-bound ERβ transcriptional 
activation, we next investigated whether the ligand-activated AR would modulate ERβ activity. 
This was based on the fact that Peters and co-workers showed that when the AR is activated by 
its natural ligand, DHT or the selective AR modulator, MPA, a concentration dependent 
decrease in ERα activity was observed as the AR levels were increased (Peters et al. 2009). We 
also used DHT and MPA for model validation, but included NET-A, a progestin previously 
reported to have similar potent androgenic activity as DHT and MPA (Africander et al. 2014). 
The human MDA-MB-231 cells were transiently transfected with 2.5 ng pSG5-ERα and 100 
ng vit-ERE-TATA-luciferase or 2.5 ng pSG5-ERβ and 50 ng vit-ERE-TATA-luciferase, in the 
absence or presence of increasing concentrations of pSVARo (2.5 ng, 5 ng, 10 ng). The cells 
were subsequently treated with 1 nM E2 in the absence or presence of 1 nM DHT, MPA or 
NET-A for 36 hours. The results in figure 3.6A-C show that inhibition of ERα transactivation 
function by the AR is not augmented by the addition of AR ligand. Surprisingly, cells 
transfected with only ERα and treated with equimolar concentrations of E2 and MPA or E2 and 
NET-A, displayed a significant decrease of E2 activity via ERα (figure 3.6B-C), suggesting that 
MPA and NET-A are ERα antagonists. None of the AR ligands displayed agonist activity via 


































































































Figure 3.6 continues on next page. 








































































































Figure 3.6 legend on next page. 
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Figure 3.6. Inhibition of ERα transcriptional activation is not enhanced in the presence of AR 
ligands. Human MDA-MB-231 breast cancer cells were transiently transfected with pSG5-hERα and 
the vit-ERE-TATA-luciferase reporter construct, in the absence or presence of increasing concentrations 
of pSVARO (1x, 2x or 4x molar excess), and where needed pGL2basic, using X-tremeGENE HP DNA 
transfection reagent according to the manufacturer’s instructions. After 3 hours, cells were treated with 
0.1% (v/v) EtOH (control) or 1 nM E2 in the absence or presence of 1 nM DHT, MPA or NET-A for 36 
hours. The luciferase values were normalised to protein concentrations, and expressed as 
luciferase/protein (luc/prot). The results indicate the average (± SEM) of at least three independent 
experiments, with each condition performed in triplicate. (A -C) The fold induction at 1 nM E2 via ERα 
was set as 100%, and induction in the presence of various concentrations of liganded AR calculated 
relative to that. (D) The fold induction at 1 nM E2, DHT, MPA and NET-A via ERα is shown. Statistical 
analysis was performed using Newman-Keuls (compare all pairs of columns) post-tests (A-C) and one-
way ANOVA analysis of variance with Bonferroni (compare all pairs of columns) post-tests (D). 
 
Similar to the results obtained for ERα, results in figure 3.7A-C indicate that the AR ligands do 
not modulate the effect of unliganded AR on the transactivation function of ERβ, and none of 
the AR ligands displayed agonist activity via ERβ (figure 3.7D). Interestingly, in contrast to the 
results seen for ERα (figure 3.6B-C), neither MPA nor NET-A had an inhibitory effect on the 
E2-induced activity of ERβ (figure 3.7B-C). Taken together, these results indicate that the 
inhibition of ERα transactivation function by the AR is independent of AR ligand. Furthermore, 
the transactivation function of ERβ is not influenced by either the unliganded or liganded AR.  
























































































Figure 3.7 continues on next page. 


































































































Figure 3.7 legend on next page. 
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Figure 3.7. Ligand bound AR does not decrease the transcriptional activity of E2 via ERβ. Human 
MDA-MB-231 breast cancer cells were transiently transfected with pSG5-hERβ and the vit-ERE-
TATA-luciferase reporter construct, in the absence or presence of increasing concentrations of pSVARO  
(1x, 2x or 4x molar excess), and where needed pGL2basic, using X-tremeGENE HP DNA transfection 
reagent according to the manufacturer’s instructions. After 3 hours, cells were treated with 0.1% (v/v) 
EtOH (control) or 1 nM E2 in the absence or presence of 1 nM DHT, MPA or NET-A for 36 hours. The 
luciferase values were normalised to protein concentrations, and expressed as luciferase/protein 
(luc/prot). The results indicate the average (± SEM) of at least three independent experiments, with each 
condition performed in triplicate. (A -C) The fold induction at 1 nM E2 via ERβ was set as 100%, and 
induction in the presence of various concentrations of liganded AR calculated relative to that, and (D) 
The fold induction at 1 nM E2, DHT, MPA and NET-A via ERβ. Statistical analysis was performed 
using two-way ANOVA analysis of variance with Bonferroni (compare all pairs of columns) post-tests 
(A-C) and one-way ANOVA analysis of variance with Bonferroni (compare all pairs of columns) post-
tests (D). 
 
3.4. AR abolishes the transcriptional activity of E2 via both ER subtypes   
on an endogenous ER regulated gene in a breast cancer cell line 
To investigate whether the results observed on the synthetic ERE-containing promoter could be 
mimicked on an endogenous ER regulated gene, the MDA-MB-21 breast cancer cell line was 
transiently transfected with 2.5 ng of either the ERα or the ERβ expression vector. The cells 
were treated with 1 nM E2 for 12 hours, followed by qPCR analysis for the mRNA expression 
of the PR, a well-known ER regulated gene, which is used as a marker for functional ER 
signalling (Han et al. 2008, Sivik and Jansson 2012). The optimal time for PR gene expression 
in the presence of both ER subtypes was 12 hours (Addendum). The results in figure 3.8A show 
that E2 upregulates PR mRNA expression in MDA-MB-231 cells transfected with either ERα 
(2.4-fold) or ERβ (1.9-fold). As a control to determine whether the E2 response was indeed via 
the particular overexpressed ER subtypes, the cell line was transfected with 2.5 ng of the empty 
vector pGL2basic. The result in figure 3.8A shows that E2 has no effect on PR gene expression 
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in the absence of the transfected ER subtypes, suggesting that the E2-mediated upregulation of 
the PR gene is ER dependent. 
Next we investigated how the presence of increasing AR concentrations would influence the 
E2-induced upregulation of the PR gene, by transfecting the MDA-MB-21 breast cancer cell 
line with 2.5 ng of either the ERα or the ERβ expression vector in the absence or presence of 
2.5, 5 or 10 ng of an AR expression vector. Note that, as we had shown that the addition of AR 
ligands in the presence of the AR did not influence ER transactivation on a synthetic ERE-
containing promoter, we did not investigate PR gene expression in the presence of the liganded 
AR. The result in figure 3.8B shows that in the presence of transfected ERα, the unliganded AR 
appears to decrease the E2-induced upregulation of the PR gene in a concentration dependent 
manner. However, the trend indicating that the decrease is concentration-dependent, was not 
statistically significant. Surprisingly, and in contrast to results on the synthetic ERE-containing 
promoter, the unliganded AR also appeared to decrease the E2-induced upregulation of the PR 
gene in the presence of transfected ERβ (figure 3.8C). 
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Figure 3.8 continues on next page. 
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Figure 3.8. The E2-induced expression of the PR gene in MDA-MB-231 breast cancer cells 
transfected with either ERα or ERβ is inhibited by the AR. Human MDA-MB-231 breast cancer 
cells were transiently transfected with pSG5-hERβ or pSG5-hERα in the absence or presence of 
increasing concentrations of pSVARO (1x, 2x or 4x molar excess), and where needed the filler plasmid 
pGL2basic using X-tremeGENE HP DNA transfection reagent according to the manufacturer’s 
instructions. After 24 hours, cells were treated with 0.1% (v/v) EtOH (control) or 1 nM E2 for 12 hours. 
Total RNA was isolated, cDNA synthesized and mRNA expression levels of PR and GAPDH were 
determined by QPCR. GAPDH was used as the internal standard and the ratio of PR mRNA 
expression/GAPDH mRNA of samples treated with E2 were calculated relative to EtOH. The fold 
induction is shown in (A), while this fold induction at 1 nM E2 via ERα (B) or ERβ (C) was set as 100%, 
and mRNA expression in the presence of various concentrations of AR calculated relative to that. 
Results indicate the average (± SEM) of four independent experiments. Statistical analysis was 
performed using one-way ANOVA analysis of variance and Bonferroni (compare all pairs of columns) 
post-tests. 
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3.5. Androgen response element transactivation via ERα but not ERβ  
It is well-known that the ER and AR activate transcription of target genes via binding to distinct 
response elements namely the ERE for ER (Kumar and Chambon 1988, Hyder et al. 1999, 
Ishida et al. 2010, Botelho et al. 2015), and the androgen response element (ARE) for AR 
(Mangelsdorf et al. 1995, Mitchell et al. 2000, Haendler et al. 2001, Matsumoto et al. 2013). 
However, recent evidence suggests that while ERα only binds to its consensus ERE, the AR 
can also bind to an ERE (Peters et al. 2009). Using promoter reporter assays, we thus next 
investigated whether either ERα or ERβ could transactivate via an ARE. MDA-MB-231 cells 
were transfected with 2.5 ng of either pSG5-ERα or pSG5-ERβ and 100 ng of the pTAT-GRE-
E1b-luc promoter-reporter construct. As most steroid receptors, except the ER (Klock et al. 
1987, Klein-Hitpass et al. 1988, Brosens et al. 2004), can bind the same DNA response element 
(Beato et al. 1989), the GRE can also serve as a response element for the AR, and is then 
referred to as an ARE. Results in figure 3.9A indicate that after treatment with 1 nM E2 or DHT 
ERβ does not transactivate via an ARE (p>0.05). Considering that Peters et al. (2009) showed 
that ERα does not bind to an ARE, we were surprised when our results indicated significant 
transactivation (p<0.001) of an ARE-containing promoter-reporter construct via ERα (figure 
3.9B). In addition, significant transactivation was also observed in the presence of 1 nM DHT 
(figure 3.9B). 
As a control to determine whether the ARE-containing promoter-reporter construct is 
transcriptionally active, cells were also transfected with the pSVARo expression vector and the 
ARE-containing promoter-reporter construct, and treated with 1 nM DHT or E2. As expected, 
induction (317-fold) was observed when cells transfected with the AR and an ARE were treated 
with 1 nM DHT (figure 3.9C), indicating that DHT and the ARE promoter-reporter construct 
are active in this cell line. No significant induction was observed with 1 nM E2 indicating that 
E2 has no agonist activity via the AR on an ARE.  
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Figure 3.9 legend on next page. 
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Figure 3.9. Unlike ERα, ERβ does not transactivate via a synthetic ARE promoter-reporter 
construct. Human MDA-MB-231 breast cancer cells were transiently transfected with (A) pSG5-hERβ, 
(B) pSG5-hERα or (C) pSVARO and a pTAT-GRE-E1b-luciferase containing promoter-reporter 
construct using X-tremeGENE HP DNA transfection reagent according to the manufacturer’s 
instructions. After 3 hours, cells were treated for 36 hours with 0.1% (v/v) EtOH (control) or 1 nM E2 
or DHT. Luciferase values were normalised to the protein concentrations, and expressed as 
luciferase/protein (luc/prot). The fold induction via ERβ (A), ERα (B) and the AR (C) on an ARE is 
shown. The results indicate the average (± SEM) of two independent experiments, with each condition 
performed in triplicate. Statistical analysis was performed using one-way ANOVA analysis of variance 
and Bonferroni (compare all pairs of columns) post-tests. 
 
3.6. E2-induced upregulation of an endogenous ARE-containing gene can 
be mediated by both ERα and β  
To investigate whether the results observed on the synthetic ARE-containing promoter could 
be mimicked on an endogenous ARE-containing promoter, the MDA-MB-21 breast cancer cell 
line was transiently transfected with 2.5 ng of either the ERα or the ERβ expression vector. The 
cells were treated with 1 nM E2 or DHT for 12 hours, followed by qPCR analysis for the mRNA 
expression of the prostate specific antigen (PSA), which is a well-known ARE-containing gene. 
In contrast to the results in figure 3.9A and B, where we observed that unlike ERα, ERβ does 
not transactivate via a synthetic ARE, the results in figure 3.10A and B show that PSA mRNA 
expression was significantly upregulated in the presence of E2 in cells transfected with either 
ERβ (6.0-fold) or ERα (2.6-fold). As expected, results from cells transfected with the AR and 
treated with 1 nM DHT showed significant upregulation (2.1-fold) of PSA gene expression 
(figure 3.10C). 
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Figure 3.10 legend on next page. 
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Figure 3.10. The E2-induced mRNA expression of an AR regulated gene (PSA) via both ERα and 
ERβ. Human MDA-MB-231 breast cancer cells were transiently transfected with (A) pSG5-hERβ (B) 
pSG5-hERα or (C) pSVARO using X-tremeGENE HP DNA transfection reagent according to the 
manufacturer’s instructions and incubated for 24 hours. Cells were subsequently treated with 0.1% (v/v) 
EtOH (control) or 1 nM E2 or DHT for 12 hours. Total RNA was isolated, cDNA synthesized and mRNA 
expression levels of PSA and GAPDH were determined by QPCR. GAPDH was used as the internal 
standard and the ratio of PSA mRNA expression/GAPDH mRNA of all samples were calculated relative 
to the sample treated with 0.1% (v/v) EtOH. Results show the PSA mRNA expression at 1 nM E2 or 
DHT via (A) ERβ, or (B) ERα or (C) AR. For A and B results indicate the average (± SEM) of two 
independent experiments, while C is the result of a single experiment. Statistical analysis was performed 
using one-way ANOVA analysis of variance and Bonferroni (compare all pairs of columns) post-tests 
(A and B) and the unpaired t-test (C).  
 
3.7. The AR inhibits the transrepression function of both ERα and ERβ 
As the ER elicits its biological effects by either activating or repressing the transcription of 
target genes (Harrington et al. 2003), this study also examined the influence of the AR on the 
transrepression function of both ERα and ERβ. MDA-MB-231 cells were transiently transfected 
with 2.5 ng of either pSG5-ERα or pSG5-ERβ and 100 ng of a synthetic IL-6NFκB3-luciferase 
promoter-reporter construct, in the absence or presence of increasing concentrations of 
pSVARo. The cells were subsequently treated with 10 ng/ml PMA in the absence and presence 
of 1 nM E2. As shown in figure 3.11A and C, stimulating the cells with PMA significantly 
induced an NFκB driven induction of 3.4-fold and 8.4-fold in the presence of ERα and ERβ, 
respectively. The PMA-induced response was then set to 100% and the E2 response via ERα 
(figure 3.11B) or ERβ (figure 3.11D) calculated as a percentage relative to that. The E2-
mediated repression on the NFκB promoter, via ERα and ERβ, was 87.8% and 48.5%, 
respectively. While the addition of increasing concentrations of the AR inhibited the E2-
mediated repression on the NFκB promoter via ERα (figure 3.11B), E2-mediated repression via 
ERβ was not affected by the AR (figure 3.11D). 
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Figure 3.11 continues on next page. 
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Figure 3.11 legend on next page. 
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Figure 3.11. The AR inhibits the transrepression function of both ERα and ERβ. Human MDA-
MB-231 breast cancer cells were transiently transfected with either (A) pSG5-hERα or (B) pSG5-hERβ 
and the IL-6NFκB3-luciferase containing promoter-reporter construct, in the absence or presence of 
increasing concentrations of pSVARO, (1x, 2x or 4x molar excess), and where needed pGL2basic, using 
X-tremeGENE HP DNA transfection reagent according to the manufacturer’s instructions. After 3 
hours, cells were treated with 0.1% (v/v) EtOH (control) in the absence or  presence of 10 ng/ml PMA 
(A and C) or 10 ng/ml PMA in the absence and presence of 1 nM E2 (B and D) for 36 hours. The 
luciferase values were normalised to protein concentrations, and expressed as luciferase/protein 
(luc/prot). The results indicate the average (± SEM) of two independent experiments, with each 
condition performed in triplicate. (A and C) EtOH+PMA induction via the NF-κB-containing promoter 
construct calculated relative to the EtOH set as 1. (B and D) The PMA-induced response was set as 
100% and the E2-induced transrepression via ERα or ERβ, in the absence or presence of AR, was 
calculated relative to that. Statistical analysis was performed using unpaired t-test (A and C) and one-
way ANOVA analysis of variance with Bonferroni (compare all pairs of columns) post-tests (B and D). 
 
It was next investigated whether the presence of an AR ligand could modulate these effects. 
The human MDA-MB-231 cells were transfected as above and were subsequently treated with 
1 nM E2 in the absence or presence of 1 nM DHT, MPA or NET-A for 36 hours. Similar to 
results in figure 3.6 showing that the inhibition of ERα transactivation function by the AR is 
not enhanced by the presence of AR ligands, results in figure 3.12A-C indicate that AR ligands 
do not influence the AR-dependent inhibition of ERα transrepression function. Surprisingly, 
although the unliganded AR had no effect on the transrepression function of ERβ, results in 
figure 3.13A-C indicate that the ligand-bound AR inhibits the transrepression function of ERβ. 
This result is in contrast to the results in figure 3.7 showing that both the unliganded and 
liganded AR had no effect on the transactivation function of ERβ. 
 
 







































































































































Figure 3.12 continues on next page. 




































































Figure 3.12. Inhibition of ERα transcriptional repression is not enhanced by the presence of AR 
ligands. Human MDA-MB-231 breast cancer cells were transiently transfected with pSG5-hERα and 
the IL-6NFκB3-luciferase containing promoter-reporter construct, in the absence or presence of 
increasing concentrations of pSVARO (1x, 2x or 4x molar excess), and where needed pGL2basic, using 
X-tremeGENE HP DNA transfection reagent according to the manufacturer’s instructions. After 3 
hours, cells were treated with 10 ng/ml PMA and 1 nM E2 in the absence or presence of 1 nM DHT, 
MPA or NET-A for 36 hours. The luciferase values were normalised to protein concentrations, and 
expressed as luciferase/protein (luc/prot). The results indicate the average (± SEM) of two independent 
experiments, with each condition performed in triplicate. The E2-induced transrepression on the NFκB-
containing promoter construct via ERα, in the absence or presence of AR, was expressed as a percentage 
calculated relative to EtOH + PMA set as a 100%. Statistical analysis was performed using one-way 
ANOVA analysis of variance with Bonferroni (compare all pairs of columns) post-tests as well as two-
way ANOVA analysis of variance with Bonferroni (compare all pairs of columns) post-tests. 
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Figure 3.13. The ligand-bound AR inhibits the E2-induced transrepression function of ERβ. 
Human MDA-MB-231 breast cancer cells were transiently transfected with pSG5-hERβ and the IL-
6NFκB3-luciferase containing promoter-reporter construct, in the absence or presence of increasing 
concentrations of pSVARO (1x, 2x or 4x molar excess), and where needed pGL2basic, using X-
tremeGENE HP DNA transfection reagent according to the manufacturer’s instructions. After 3 hours, 
cells were treated with 10 ng/ml PMA and 1 nM E2 in the absence or presence of 1 nM DHT, MPA or 
NET-A for 36 hours. The luciferase values were normalised to protein concentrations, and expressed as 
luciferase/protein (luc/prot). The results indicate the average (± SEM) of two independent experiments, 
with each condition performed in triplicate. The E2-induced transrepression on the NFκB-containing 
promoter construct via ERβ, in the absence or presence of AR, was expressed as a percentage calculated 
relative to EtOH + PMA set as a 100%. Statistical analysis was performed using one-way ANOVA 
analysis of variance with Bonferroni (compare all pairs of columns) post-tests as well as two-way 
ANOVA analysis of variance with Bonferroni (compare all pairs of columns) post-tests. 
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3.8. No change in proliferation was observed in cells transfected with ER 
Cell proliferation assays were used to investigate E2-induced proliferation of the MDA-MB-
231 breast cancer cell line when transiently transfected with either ERα or ERβ, and how 
proliferation could be modulated by the presence of overexpressed AR. The MDA-MB-231 cell 
line was thus transfected with 2.5 ng of the expression vectors for either pSG5-ERα, pSG5-ERβ 
or the pGL2basic empty vector. The latter was used as a control to determine if E2-induced cell 
proliferation was indeed via the overexpressed ER subtypes. As expected, no cell proliferation 
was observed for cells transfected with the empty vector (figure 3.14). Surprisingly, however, 
no E2-induced cell proliferation was detected when cells were transfected with either ERα or 




















































Figure 3.14 legend on next page. 
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Figure 3.14. Human MDA-MB-231 breast cancer cells were transiently transfected with pGL2basic 
(empty vector) or pSG5-hERα or pSG5-hERβ or using X-tremeGENE HP DNA transfection reagent 
according to the manufacturer’s instructions. After 24 hours these cells, as well as untransfected MDA-
MB-231 cells, were treated for 48 hours with 0.1% (v/v) EtOH (control) or 1 nM E2. The results indicate 
the relative fold cell proliferation under various conditions with the value for cells treated with EtOH 
for each condition (control) set as 1. The average (± SEM) of at least four independent experiments, 
with each condition performed in triplicate is shown. Statistical analysis was performed using one-way 

































Steroid receptors play an important role in the pathogenesis of breast cancer and understanding 
their clinical significance is a crucial aspect of breast cancer research (Welboren et al. 2007, 
Han 2014, Sabatier et al. 2014). The ER is the most common and well established breast cancer 
biomarker, with 75% of breast cancers being ER-positive. The ER exists as two subtypes, ERα 
and ERβ, which are transcription factors that modulate the expression of target genes (Couse 
and Korach 1999). The activated ERα stimulates breast cancer cell proliferation by regulating 
specific genes involved in the cell cycle (Frasor et al. 2003, Hartman et al. 2009), while ERβ 
has been shown to regulate a variety of target genes resulting in ERβ opposing the actions of 
ERα (Hartman et al. 2009). For example, E2-induced ERα stimulates breast cancer cell 
proliferation by activating cyclin D1, an oncogene which regulates G1-S cell cycle progression, 
while ERβ is anti-proliferative as it inhibits cyclin D1 activation (Paech et al. 1997, 
Weatherman et al. 2001, Liu et al. 2002). Due to the distinct roles of ERα and ERβ in breast 
cancer, several studies have suggested that blocking the activity of ERα, but not ERβ, is an 
effective treatment option for breast cancer (Assikis and Craig 1997). 
Although the role of the ER subtypes in breast cancer pathogenesis has been well-characterized, 
recent studies are also exploring the role of other steroid receptors (Peters et al. 2009, Need et 
al. 2012, Obr and Edwards 2012, Skor et al. 2013, Cochrane et al. 2014, Knutson and Lange 
2014, Pistelli et al. 2014, Rechoum et al. 2014, Abduljabbar et al. 2015). For example, as the 
AR is expressed in 70% of breast cancer tumours (Birrell et al. 1998, Schippinger et al. 2006, 
Lin et al. 2009, Hu et al. 2011, Chottanapund et al. 2013), many clinical (Hu et al. 2011, Park 
et al. 2011, Pistelli et al. 2014) and molecular  studies (Peters et al. 2009, Chottanapund et al. 
2013, Cochrane et al. 2014, Rechoum et al. 2014) are investigating the role of the AR and 
androgens in breast cancer. Of particular interest is the fact that AR signalling is known to exert 
anti-estrogenic effects (Dauvois et al. 1991, Ando et al. 2002) suggesting crosstalk between the 
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ER and AR signalling pathways. Indeed, the study by Peters and co-workers showed that both 
the unliganded and liganded AR has the ability to inhibit the activity of ERα (Peters et al. 2009). 
In agreement with this, two other studies have also reported interplay between ERα and AR 
transcriptional pathways (Need et al. 2012, Rechoum et al. 2014). Whether crosstalk also exists 
between the AR and ERβ in breast cancer cells is not well-studied and thus formed the basis of 
this thesis. In chapter 3, it was thus investigated whether the unliganded and/or ligand-bound 
AR, could modulate the transcriptional activity (transactivation and transrepression) of ERβ in 
the human MDA-MB-231 breast cancer epithelial cell line. 
 
4.2. Validating the model system 
In the first part of this thesis, using western blot analysis (figure 3.1), previous reports in the 
literature indicating that the human MDA-MB-231 breast cancer cell line does not express the 
ER subtypes and the AR was confirmed (Horwitz et al. 1978, Lazennec and Katzenellenbogen 
1999, Leo et al. 2004, Buchanan et al. 2005, Abduljabbar et al. 2015). This result, together with 
previous reports that the MDA-MB-231 cells do not express the PR, but express the GR and 
the MR,  suggests that the human MDA-MB-231 cell line is an appropriate model cell line for 
comparing the activities of specific transiently transfected steroid hormone receptors.  
Next, the experimental conditions used in the study by Peters et al. (2009) were mimicked, and 
in agreement with their results, the current study showed that the unliganded AR (figure 3.2B) 
inhibits the transcriptional activation of ERα (figure 3.2B). However, Peters and co-workers 
showed that the decrease in ERα transcriptional activation increased as the amount of liganded 
AR, activated by either the natural androgen DHT or the selective AR modulator MPA 
(MacLaughlin and Richardson 1979, Teulings et al. 1980, Birrell et al. 1998), was increased. 
The current study, on the other hand, showed that a concentration-dependent decrease in the 
transcriptional activation of ERα was observed in the presence of the unliganded AR, and that 
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the AR ligand (DHT, MPA or NET-A (a progestin with androgenic activity (Africander et al. 
2014)), did not increase this effect (figures 3.2B; figures 3.6A-C). Furthermore, consistent with 
the result of Peters et al. (2009), the western blot analysis in figure 3.3 clearly indicates that the 
inhibition of ERα transcriptional activation by the AR was not due to the AR decreasing ERα 
protein levels.  
Furthermore, our results show that MPA and NET-A, but not DHT antagonize the E2-induced 
agonist activity for transactivation via ERα (figure 3.6B and C). It is known that progestins that 
exert androgenic properties, like MPA, are anti-estrogenic (Clarke and Sutherland 1990, 
Dauvois et al. 1991, Ando et al. 2002) via a mechanism that does not involve ER binding 
(Leung et al. 1981, Vignon et al. 1983, Sutherland et al. 1988). For example, it has been shown 
that MPA decreases intracellular E2 levels as a result of it enhancing 17β-HSD2 activity, which 
causes the conversion of E2 to E1 (Dauvois et al. 1991, Pasqualini 2003). Considering that NET-
A, like MPA, has potent androgenic properties (Africander et al. 2014), and that 17β-HSD type 
1 and type 2 are expressed in MDA-MB-231 cells (Day et al. 2006, Newman et al. 2006), it is 
likely that the anti-estrogenic activity seen by both MPA and NET-A is due to these ligands 
increasing 17β-HSD2 expression and activity.  
 
4.3. Effects on synthetic promoter-reporter genes are not always 
reflected on endogenous genes 
Having validated the model system used by Peters et al. (2009) for ERα, we next used a similar 
model system to investigate the effect of the AR on the transactivation function of ERβ. Results 
in figure 3.5B showed that when MDA-MB-231 cells were co-transfected with the ERβ cDNA 
expression vector and increasing concentrations of the AR expression vector, the unliganded 
AR did not affect the E2-induced transcriptional activation of ERβ. These findings are 
consistent with a previous study in CV-1 monkey kidney cells showing that co-expression of 
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the liganded AR with ERβ did not cause a significant decrease in ERβ transactivation (Panet-
Raymond et al. 2000). Furthermore, our investigations in the presence of AR ligands (DHT, 
MPA, NET-A) showed that, like the unliganded AR, ligand-bound AR has no effect on the 
transactivation function of ERβ on a simple ERE (figure 3.7). Interestingly, using a yeast two-
hybrid assay, Panet-Raymond and co-workers showed no interaction between the AR and ERβ, 
but like Peters et al. (2009) showed an interaction between the AR and ERα (Panet-Raymond 
et al. 2000, Peters et al. 2009). Interestingly, these observations occurred in the presence of 
either unliganded or liganded receptors. Several molecular mechanisms have been proposed on 
how the AR suppresses the transactivation function of ERα (Fioretti et al. 2014). For example, 
the AR and ERα have been shown to directly interact with each other thus preventing the latter 
from binding to EREs and as it has also been shown that the AR can bind to both synthetic and 
endogenous EREs (Peters et al. 2009, Fioretti et al. 2014), it can compete with ERα for binding 
to the EREs. 
We next determined the effects of increasing amounts of unliganded AR on the mRNA 
expression of the endogenous PR gene. The PR is a well-known ER regulated gene, and its 
expression in breast cancer cells is used as a marker for functional ER signalling (Clarke et al. 
1994, Yang et al. 2001, Rickard et al. 2002, Han et al. 2008). Furthermore, it has previously 
been shown that E2-activated ERβ, like ERα, enhances the expression of the endogenous PR 
gene in the uterine and bone cells (Schultz et al. 2005). Surprisingly, although we showed that 
the AR, both unliganded and liganded, had no effect on ERβ-mediated transactivation in an 
ERE-reporter assay (figure 3.5B and 3.7A-C), the results in figure 3.8C showed that the 
unliganded AR downregulates the ERβ-mediated regulation of the endogenous PR gene. In 
contrast, the ability of the unliganded AR to inhibit ERα-mediated transactivation on the 
synthetic promoter-reporter gene (figure 3.2B) was replicated on the endogenous PR gene 
(figure 3.8B) with a similar percentage reduction observed at the higher AR concentrations (2- 
and 4-fold). These results indicate that although effects seen on a synthetic promoter-reporter 
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can often be reproduced on an endogenous gene, this is not always the case. Effects on the 
synthetic promoter are likely due to the AR and ERα competing for binding to ERE, as 
previously reported by Peters et al. (2009). However, considering that the AR inhibits the 
endogenous PR gene in the presence of either ERα or ERβ, it may be that effects on the 
endogenous promoter is more complex than effects on a simple synthetic ERE-promoter. 
Although the general mechanism for transactivation is via the interaction of the activated ER 
with EREs in target genes, the human PR does not contain a palindromic ERE (Misrahi et al. 
1988, Kastner et al. 1990, Schultz et al. 2005). Instead, it contains an ERE half-site and two 
specificity protein (Sp1) sites, all of which were previously shown to be needed for E2-mediated 
activation of the PR gene (Schultz et al. 2003, Petz et al. 2004). Thus it may mean that ERα- 
and ERβ-mediated activation of the endogenous PR gene by E2, requires both the ERE half site 
and the Sp1 sites. The possibility that the AR competes with either ERα or ERβ for the ERE 
half-site, can thus not be excluded. Furthermore, as the AR has been shown to repress Sp1-
induced transcription (Curtin et al. 2001, Verras et al. 2007, Grosse et al. 2012), it may be 
possible for the AR to compete with both ERα and ERβ for tethering to Sp1, thereby inhibiting 
the activation of the PR gene. Taken together, we suggest a putative mechanism whereby the 
AR and ERα, but not ERβ, compete for binding to the synthetic ERE, while on the endogenous 
PR gene both ERα and ERβ compete with the AR for binding to either the ERE half-sites and/or 
for tethering to Sp1. However, further studies are needed to support this hypothesis. 
 
4.4. E2 upregulation of the endogenous ARE-containing PSA gene can be 
mediated by either ERα or ERβ  
As mentioned previously, Peters and co-workers showed that the AR can bind to either an ARE 
or ERE, while ERα only binds to an ERE (Peters et al. 2009). However, we showed that E2 via 
ERα could transactivate a simple ARE-containing promoter (figure 3.9B), as well as 
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upregulating the mRNA expression of the endogenous ARE-containing PSA gene in MDA-
MB-231 cells (figure 3.10B). These results suggest, at least for the simple ARE in the current 
experimental system that ERα binds to the ARE. In addition, we show that E2 upregulated PSA 
mRNA expression in the presence of overexpressed ERβ (figure 3.10A) but did not 
transactivate the simple ARE via ERβ (figure 3.9A), yet again, indicating that effects seen on a 
synthetic promoter cannot always be reproduced on an endogenous gene, and that regulation of 
an endogenous gene is more complex than regulation of a simple synthetic promoter. For the 
endogenous PSA gene, the possibility that ERα and ERβ could be interacting with cis-elements 
other than the ARE in the PSA promoter cannot be excluded. It is known that Sp1 binding sites 
are found in the PSA promoter (Sadar et al. 1999, Kim and Coetzee 2004), and as previously 
mentioned, it is known that ERα can tether to the Sp1 transcription factor to activate the 
transcription of the Sp1 containing PR gene (Petz et al. 2004, Schultz et al. 2005). Surprisingly, 
a 6.0-fold increase in the expression of the PSA gene was observed in the presence of ERβ and 
E2 (figure 3.10A), while only a 2.1-fold was seen in the presence of the AR and DHT (figure 
3.10C). However, it should be noted that the latter was the result of a single experiment, and 
should be repeated before any conclusions are made. 
Interestingly the results in figure 3.9B showed that DHT also activates the simple ARE-
containing promoter via ERα (a 3.7-fold increase). Although it appears that a similar activation 
(1.8-fold) of the endogenous PSA gene occurs (figure 3.10B), it was not statistically significant. 
To the best of our knowledge, there are no reports in the literature on the activation of ERα by 
DHT. However, at least one study has reported that DHT binds weakly to rat ERα and ERβ 
(Kuiper et al. 1997).  
In summary, our results in MDA-MB-231 cells indicating that ERα can transactivate an ARE-
containing promoter/gene are in contrast to the findings reported by (Peters et al. 2009) showing 
that ERα cannot bind to AREs in COS-1 and T47D cells. Taking into consideration that 
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receptors and their hormones behave differently in different cell lines (Birrell et al. 1998), the 
discrepancy in results could be due to the different techniques and/or cell lines used.  
 
4.5. The unliganded AR impedes repression of transcription via ERα, but 
not ERβ, while the liganded AR impedes the transrepression function 
of both ERα and ERβ. 
Most studies on the ER focus on the mechanism by which ERs regulate the transcription of E2 
regulated genes via direct binding to EREs. As described in Chapter 1 (Section 1.3.2.2), the 
ERs can also repress transcription of target genes by tethering to other DNA-bound 
transcription factors such as NFκB (Stein and Yang 1995, Galien and Garcia 1997). Thus, we 
next investigated whether the AR could modulate repression of transcription via the ER 
subtypes. In agreement with previously reported studies (Stein and Yang 1995, Galien and 
Garcia 1997, Visser et al. 2013), we showed that E2 repressed the PMA-induced activation of a 
simple NFκB-containing promoter-reporter construct via both ERα and ERβ (figure 3.11B and 
D). 
Similar to the results for transactivation of a simple ERE-containing promoter-reporter 
construct showing that the unliganded AR inhibits the transactivation function of ERα but not 
of ERβ (figure 3.2B and 3.5B), the results in figure 3.11B and 3.11D show that the unliganded 
AR inhibits the E2-induced repression of NFκB activity via ERα but not via ERβ. To the best 
of our knowledge, this study is the first to show that the AR can modulate the transrepressive 
effects of E2 via ERα. It is noteworthy that this modulation by the AR is not seen for ERβ. The 
inhibition noted in the case of ERα may be due to the unliganded and liganded AR interacting 
with ERα, physically preventing ERα from tethering to NFκB.  
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As seen for transactivation, the AR ligands do not modulate AR effects on ERα-mediated 
transrepression. Surprisingly, the results in figure 3.12A-C show that ligand-bound AR was 
able to inhibit the transrepression function of ERβ. Additional studies are needed to elucidate 
the mechanism behind this finding, as well as to evaluate its physiological impact. Considering 
that both the AR and ER subtypes can tether to NFκB leading to repression (Palvimo et al. 
1996, Aarnisalo et al. 1998, McKay and Cidlowski 1999), it may be possible that the AR and 
ER subtypes are competing for binding to NFκB, thus the activated AR may prevent ERβ from 
causing transrepression thereby inhibiting the ER-mediated anti-inflammatory effects of E2. It 
is known that inflammation plays an important role in breast cancer development and 
progression (Niu et al. 2012, Bhatelia et al. 2014, Suman et al.), thus our results showing that 
the AR reduces the anti-inflammatory effects of the ER may suggest that inflammation-induced 
breast cancer progression is promoted. However further studies are needed to assess the link 
between the ER, inflammation and breast cancer. 
 
4.6. No change in proliferation was observed in cells transfected with ER  
Transactivation and transrepression of ER target genes aid in the regulation of breast cancer 
cell proliferation (McKay and Cidlowski 1999, Beato and Klug 2000). Since the results from 
the current study showed that the unliganded AR could inhibit the transactivation and 
transrepression function of ERα, but not of ERβ, using simple ERE- and NFkB-containing 
promoter reporter constructs, we next evaluated the effects of the AR on E2-stimulated 
proliferation of the human MDA-MB-231 breast cancer cell line. A MTT cell proliferation 
assay was thus performed in MDA-MB-231 cells transfected with either ERα or ERβ in the 
absence of the AR. As we did not detect E2-induced proliferation in either the untransfected 
MDA-MB-231 cells or in those with overexpressed ERα or ERβ (figure 3.14), we could not 
evaluate the modulatory effects of the AR on cell proliferation.  
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Upon closer inspection of the literature, it appears that most studies employ the ER-positive 
MCF-7 breast cancer cell line (Han et al. 2008, Zhang et al. 2013) when investigating E2-
mediated cell proliferation. This is probably due to the fact that a number of studies have shown 
that cell proliferation is inhibited when ERα or ERβ is reintroduced into MDA-MB-231 cells 
(Garcia et al. 1992, Levenson and Jordan 1994, Lazennec et al. 2001, Moggs et al. 2005). 
A possible explanation for the discrepancy in the results in the current study showing no 
proliferation versus the above-mentioned studies showing inhibition of proliferation, may be 
due to different experimental conditions used. For example, Garcia et al. (1992) treated MDA-
MB-231 cells for 9 days and Lazennec et al. (2001) treated for 6 days, while in the current study 
cells were incubated for only 2 days. Furthermore, understanding why E2 has an inhibitory 
effect on the proliferation of ER-negative cells when the ER is re-introduced, is a topic under 
investigation by a number of researchers (Garcia et al. 1992, Lazennec et al. 2001, Moggs et 
al. 2005).  
 
4.7. Conclusions and Future Work 
Several studies have shown that E2 and ER play critical roles in breast cancer biology and their 
role in breast cancer has been extensively studied (Leygue et al. 1998, Speirs et al. 1999, 
Helguero et al. 2005, Yager and Davidson 2006, Zhao et al. 2008, Hartman et al. 2009). The 
ERα has been reported to promote cell growth and survival, while ERβ inhibits the ERα-
mediated cell proliferation (Leygue et al. 1998, Dotzlaw et al. 1999, Speirs et al. 1999, Zhao et 
al. 2008). The role of other steroid receptors such as the AR in breast cancer is, however, an 
area of ongoing research, with emerging evidence suggesting that the AR is also involved in 
the regulation of breast cancer growth (Birrell et al. 1998, Brys 2000, Hartman et al. 2012, Shah 
et al. 2013, Lakis et al. 2014). For example, previous evidence suggests that the AR has the 
ability to inhibit the transactivation function of ERα, with not much known about the crosstalk 
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between the AR and the ERβ. Considering that the presence of either the AR or ERβ in ERα-
positive breast cancers has been shown to be beneficial (Birrell et al. 1995, Szelei et al. 1997, 
Lanzino et al. 2005, Macedo et al. 2006, Williams et al. 2007, Hartman et al. 2009, Peters et 
al. 2009, Hickey et al. 2012), and that there is a lack of research investigating the interplay 
between the AR and ERβ in breast cancer, the aim of the current study was to elucidate the 
effects of the AR on the activity of ERβ. 
The results presented in Chapter 3, showed that although the AR has no effect on the 
transactivation function of ERβ on a simple, synthetic ERE-containing promoter, it 
downregulates the ERβ-driven mRNA expression of the endogenous PR gene, a well-described 
ER-regulated gene. Considering that upregulation of this ER-regulated gene is associated with 
an increased risk of breast cancer (Fox et al. 2008, Han et al. 2008, Sivik and Jansson 2012) 
and evidence shows that ERβ acts like ERα when expressed in breast cancers lacking ERα, our 
results suggest that the AR may have a protective role in breast cancers expressing either ERβ 
or ERα. However, in inflammation-induced breast cancer the AR may not be protective 
considering results obtained in the current study for transrepression. Specifically, for 
transrepression studies, we show for the first time that both the unliganded- and ligand-bound 
AR inhibits the transrepression function of ERα, while only the ligand-bound AR was able to 
inhibit the transrepression function of ERβ. As it is known that inflammation plays a role in the 
development and progression of breast cancer (Niu et al. 2012, Bhatelia et al. 2014, Suman et 
al. 2015), our results suggest that the unliganded- or ligand-bound AR may promote breast 
cancer risk by reducing the anti-inflammatory effects of ERα, while the AR can only do so for 
ERβ when ligand bound. Furthermore, the current study also shows ERα-mediated, E2-induced 
transactivation via a synthetic ARE as well as via an endogenous ARE-containing promoter, 
while the same is true for ERβ only via an endogenous ARE-containing promoter. It is 
interesting to note that ERβ seems to be upregulating the transcription of the endogenous PR 
and PSA genes via a mechanism involving tethering of ERβ to the Sp1 transcription factor. 
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While we cannot exclude that ERα also acts via tethering to Sp1, it appears that ERα activates 
transcription primarily via binding to EREs. 
 
To the best of our knowledge this study is the first to show that the activated AR affects the 
transrepression function of both ERα and ERβ on a synthetic NFκB-containing promoter. A 
limitation of this study is that we did not investigate the influence of the AR on ER-mediated 
transrepression of any endogenous NFκB-containing promoters. This could be addressed on 
endogenous genes such as interleukin (IL)-6 or Regulated on Activation, Normal T-cell 
Expressed, and Secreted (RANTES) (Luboshits et al. 1999, Knüpfer and Preiß 2007), which 
are known to be involved in the development and progression of breast cancer and contain 
NFκB-binding sites within their promoters (Libermann and Baltimore 1990, Li and Bever 2001, 
Azenshtein et al. 2002). To investigate whether the presence of the AR inhibits the ability of 
the ER subtypes to tether to NFκB, as suggested in Section 4.5, co-immunoprecipitation (Co-
IP) and/or fluorescence resonance energy transfer (FRET) assays may be used. Co-IP assays 
are used investigate protein-protein interactions in vitro (Fields and Song 1989), while the 
FRET assay allows the investigation of protein-protein interaction in living cells (Clegg 1995). A 
further limitation was that we did not plate into a 10 cm dish for transfections, therefore protein 
concentration was not the best normalization method.  
 
Lastly, as no E2-stimulated proliferation could be obtained in the ER-negative breast cancer cell 
line containing overexpressed ERα or ERβ, the effect of the AR on ER-mediated cell 
proliferation could not be investigated. Proliferation assays should thus be carried out in a cell 
line which is known to express both ER subtypes such as the MCF-7 or T47D breast cancer cell 
line. The role of the AR on ERα- or ERβ-mediated breast cancer cell proliferation can be 
determined in these cell lines by silencing the expression of the respective ER subtype using 
siRNA technology 
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To gain more insight into how the AR modulates ERβ-mediated regulation of the PR gene, 
chromatin immunoprecipitation (ChIP) assays can be used to firstly determine whether ERβ is 
recruited to cis-elements such as the ERE-half sites and/or Sp1 binding sites in the PR promoter. 
Secondly, ChIP can be used to determine whether the AR competes with ERβ for binding to 
the above-mentioned cis-regulatory elements as it has previously been shown that the AR can 
bind to the ERE and can tether to the Sp1 (Curtin et al. 2001, Verras et al. 2007, Peters et al. 
2009, Grosse et al. 2012). The ChIP assay is considered a relatively inexpensive method to 
study the interaction between a protein and a specific DNA sequence in vivo. Furthermore, to 
establish whether the AR interacts with ERβ and the Sp1 transcription factor to form a complex 
on the promoter of the PR gene, sequential chromatin immunoprecipitation (re-ChIP) assays 
may be employed. The mechanism whereby ERα and ERβ upregulates the mRNA expression 
of the PSA gene, which contains AREs, Sp1 binding sites as well as other cis regulatory 
elements, can also be further investigated by ChIP assays. Besides studying the recruitment of 
the ER subtypes to the Sp1 cis-regulatory element, similar experiments as described above may 
be used to determine whether the ER subtypes interact with the Sp1 transcription factor on the 
PSA promoter. 
To examine whether the Sp1 transcription factor is required for ERβ-mediated upregulation of 
PR gene expression, siRNA technology can be used to silence the expression of Sp1. In 
addition, it would be interesting to examine the effects of the AR on other ERβ-regulated 
endogenous genes such as cathepsin D (CTSD) (Behrens et al. 2007), as it has previously been 
shown that the AR inhibits the expression of the ER regulated PR gene, but not the CTSD gene 
(Peters et al. 2009). Lastly, although the use of a yeast two-hybrid assay has previously shown 
that the AR and ERβ do not interact with each other, it would be of interest to determine whether 
a direct association between these steroid receptors exists in our model system. The latter could 
be investigated using either Co-IP or FRET assays.  
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In summary, the results presented in this thesis showing that the AR inhibits the activity of ERα 
via a synthetic ERE-promoter as well as an endogenous ER-regulated gene and that of ERβ via 
an endogenous ER-regulated gene, may suggest that the presence of AR is also a good 
prognostic marker for breast cancer patients as previously reported for ERα by Peters et al. 
(2009). On the other hand, our novel results showing that the activated AR reduces the anti-
inflammatory effects of the ER, may suggest that the AR promotes inflammatory-induced 
breast cancer. The precise physiological implications of these results remain to be determined. 
Finally, although the results from this study are preliminary and have certain limitations, it 
nonetheless highlights the fact that the role of the AR in breast cancer is a complex one. Our 
findings may thus aid in understanding of crosstalk between the ER and AR signalling 
pathways, and how it contributes to the growth and survival of breast cancer cells. Figure 4.1 
shows the contribution of findings of this current study to the existing knowledge on the 
interplay between the AR and ERβ. 




Figure 4.1. Interplay between the ER subtypes and the AR may lead to both positive and negative 
effects on breast cancer. ERα promotes cell survival and proliferation, while ERβ antagonizes ERα-
mediated cell proliferation. The AR has been shown to have the ability to inhibit cell proliferation both 
directly and indirectly by suppressing the activity of ERα. The AR also has no effect on the activity of 
ERβ on synthetic ERE-containing promoter, while the AR inhibits the upregulation of the ER-regulated 
PR gene. Lastly the AR promotes inflammation-induced breast cancer by inhibiting the transrepression 
function of both ERα and ERβ. – and Τ denote inhibition of activity, + shows activation of activity, the 
yellow circle with a line inside indicates no effect on the activity, the blue arrows demonstrate that the 
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Realtime quantitative polymerase chain reaction (qPCR) 
Realtime quantitative PCR is a powerful method used for the measurement of gene expression 
(Celi et al. 1994). qPCR is based on the original PCR method that employs forward and reverse 
primer sequences that are specific for certain target genes. However, qPCR has been modified 
to involve the use of fluorescent dyes or probes (Pfaffl 2001, Huang et al. 2014, Navarro et al. 
2015). Fluorescent dyes such as SYBR-green are used during qPCR as it binds to the minor 
groove of the double stranded DNA. The use of SYBR-green allows simultaneous PCR 
amplification, detection of the PCR product, quantification of the new double stranded DNA 
being formed and lastly verification of the PCR product using melt curve analysis (Morrison 
and Weiss 1998, Phillips et al. 2009). However, there are certain factors that should be 
considered when conducting qPCR such as making sure that the reference gene does not give 
any expression under the experimental conditions as well as using RNA that is of good quality 
(Bustin 2002, Udvardi et al. 2008). 
To assess gene expression, high quality, intact RNA has to be isolated to ensure that 
experimental results obtained are reliable as poor quality RNA can compromise results. RNA 
quality was assessed by determination of the optical density (OD) at 260 nm (nucleic acids) and 
the 280 nm (proteins), followed by analysis on a 1% denaturing formaldehyde agarose gel. The 
latter is to analyse the quality and integrity of RNA isolated from the cells as the 260 nm OD 
reading can be compromised by the presence of genomic DNA (Sambrook et al. 1989). An OD 
260/280 ratio between 1.9 and 2.1 indicates that the RNA is pure (Sambrook et al. 1989). As 
shown in figure A1, the intact total RNA isolated from the MDA-MB-231 cells showed sharp, 
clear 28S and 18S RNA bands. As the 28S RNA band is approximately twice the intensity of 
the 18S RNA band, it is a good indication that the RNA is intact (Krebs et al. 2009). If the 28S 
and 18S RNA bands appearance as a smear, it is an indication that the RNA is degraded, while 
genomic DNA does not migrate through the gel because of its size (Sambrook et al. 1989). 




Figure A1. A representative 1% denaturing formaldehyde agarose gel showing the intact total 
RNA isolated from MDA-MB-231 cells. Total RNA was isolated from MDA-MB-231 cells transiently 
transfected with 2.5 ng pGL2basic, ERα or ERβ, as described in section 2.6 of Chapter 2. A total of 1 
µg RNA was electrophoresed on a 1% agarose gel and visualised by ethidium bromide staining. 
 
The intact RNA was then used to synthesize complementary DNA (cDNA) as described in 
section 2.6 of Chapter 2.  
 
Determination of primer pair efficiency 
To calculate the relative expression of the genes of interest by the method of (Pfaffl 2001), the 
primer efficiencies have to be determined. Primer efficiency is generally assumed to be two, 
since the product is doubled after every PCR cycle (Pfaffl 2001). To determine the primer 
efficiency, a serial dilution of a single cDNA sample was made, and each dilution was analysed 
in triplicate. A no template control was added, to determine if any contamination or primer self-
amplification occurred. The samples were then analysed using the qPCR protocol described in 
section 2.7 of Chapter 2. A standard curve was generated using the StepOne™ software by 
plotting the cycle number (CT) (Y-axis) for each dilution against the log of the cDNA 
concentration (X-axis) (figure A2). The slope obtained from the standard curve is then used to 
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calculate the exponential amplification value (E), which is the primer efficiency for each primer 
pair, by using the following equation (Pfaffl 2001). 
 
                               E = 10(-1/slope)                                                                (Equation 1) 














Figure A2. Representative standard curve showing cycle number (CT) versus the log DNA 
concentration for the (A) PR, (B) PSA and (C) GAPDH genes, respectively. The slope obtained from 
the each graph was used to calculate the primer efficiency.  
 
Melting curve analysis 
Melting curves are used as a way of optimization to confirm primer specificity, to determine 
whether there are any non-specific products and primer dimers. Primer dimers are indicated by 
the presence of small peaks that protrude from the product peak, while non-specific products 
can be indicated by the presence of peaks that deviate from the melting temperature (Tm) line 
(indicated by the  vertical blue line in figure A3). During the PCR reaction SYBR green forms 
complexes with the double stranded DNA products. Therefore the fluorescence measured using 
SYBR green is the measurement of the sum of the relative levels of all products formed during 
the reaction. It is very important to ensure that the measured fluorescence is of a single product. 
This is done by increasing the temperature of the samples by 0.2oC per second until the 
product’s denaturation temperature of 95oC is passed. The melting curve of a PCR product is 
dependent on the GC/AT content, length and sequence of the PCR product (Ririe et al. 1997). 
A melting curve is generally a plot of fluorescence as a function of temperature, and one product 
is indicated by one peak of high amplitude on the melting curve (Ririe et al. 1997). Examples 
C 
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of melting curves for PR, PSA and GAPDH, respectively are shown below in figure A3, and a 
2% agorose gel was used to further confirm that a single amplicon of the correct size was 




Figure A3 continues on next page. 
A 





Figure A3 legend on next page. 
B 
C 
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Figure A3. Representative melting curves for the PR, PSA and GAPDH genes, respectively. MDA-
MB-231 cells were transfected with (A and C) pSG5-ERβ and subsequently treated with 1 nM E2, while 
MDA-MB-231 cells transfected with (B) pSVARo were treated with 1 nM DHT. The red line represents 
samples treated with 1 nM E2, the blue line indicates samples treated with 1 nM DHT and the grey line 
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Figure A4 Representative agarose gels showing qPCR products of (A) PR, (B) PSA and (C) 
GAPDH. Human MDA-MB-231 breast cancer cells were transfected with 2.5 ng (A) and (C) pSG5-
hERβ or (B) pSVARO using X-tremeGENE HP DNA transfection reagent according to the 
manufacturer’s instructions for 24 hours. Cells were subsequently treated with 1 nM E2 (PR and 
GAPDH) or DHT (PSA) for 12 hours. Total RNA was isolated, cDNA synthesized and mRNA 
expression levels of PR, PSA and GAPDH were determined by qPCR. The products were 
electrophoresed on a 2% agarose gel and visualized using ethidium bromide staining. Lane 1 represents 
the no template control, while lane 2 represents the single PCR amplicon of the correct size.  
 
Determination of relative gene expression values 
Having determined that a single amplicon of the correct size had been amplified, the relative 
expression (R) levels of the gene of interest were calculated using the mathematical model 
below (Pfaffl 2001), and expressed relative to the expression levels of the vehicle control 
(EtOH)  





                          (Equation 2) 
The crossing point (CP) is the point in the PCR cycle where the target amplicon is first detected, 
and can also be referred to as the cycle number (Ct). Ct is used in ABI Prism
® literature (Applied 
Biosystems, USA), while CP is used in LightCycler®  literature (Roche Applied Science, USA) 
(Wong and Medrano 2005). The ∆CP is calculated for both the target and reference genes 
(GAPDH), by subtracting the CP value of the treated sample from the CP value of the vehicle 
control (EtOH) (Pfaffl 2001). A ratio of one indicates that there is no difference between the 
treated sample and that of the vehicle control. Results of experiments are graphically presented 
by plotting the cycle number versus the log concentration of the amplified cDNA. 
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Determining the optimal time for gene expression 
MDA-MB-231 cells were transfected with 2.5 ng of either ERα, ERβ, AR or the pGL2 basic 
empty vector for 24 hours. The cells transfected with ERα, ERβ or pGL2 basic were treated 
with 0.1% EtOH or 1 nM E2, while cells transfected with the AR were treated with 0.1% EtOH 
or 1 nM DHT for 2, 6, 12 or 24 hours.  As shown in figure A5 A, E2 did not upregulate the 
expression of the PR gene at any of the four time points in cells transfected with the empty 
vector. In contrast, cells transfected with ERα or ERβ showed significant E2-induced 
upregulation of the PR gene (figure A5 B and C). Similarly, significant DHT-induced 
upregulation of the PSA gene was seen in cells transfected with the AR (figure A5 D). As good 
induction of both the PR (4.5-fold in the presence of ERα; 3.5-fold in the presence ERβ) and 
PSA genes (2.1-fold in the presence of the AR) were observed at 12 hours, this treatment time 
was chosen for all subsequent experiments. 



































































































































































Figure A5 legend on next page. 
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Figure A5. Optimal gene expression for human PR and PSA. Human MDA-MB-231 breast cancer 
cells were transfected with 2.5 ng (A) pGl2 basic or (B) pSG5-hERα or (C) pSG5-hERβ or (D) pSVARO 
using X-tremeGENE HP DNA transfection reagent according to the manufacturer’s instructions for 24 
hours. Cells were subsequently treated with 0.1% (v/v) EtOH (control) or 1 nM E2 (PR) or DHT (PSA) 
for 2, 6, 12 and 24 hours. Total RNA was isolated, cDNA synthesized and mRNA expression levels of 
PR, PSA and GAPDH were determined by QPCR. GAPDH was used as the internal standard and the 
ratio of PR or PSA mRNA expression/GAPDH mRNA of all samples were calculated relative to the 
sample treated with 0.1% (v/v) EtOH. Results indicate the PR mRNA expression at 1 nM E2 via (A) 
pGl2 basic or (B) ERα or (C) ERβ. (D) Results indicate the PSA mRNA expression at 1 nM DHT via 
AR.   
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